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Abstract
Navigating psychotropic treatment use for bipolar disorder (BD) in pregnancy is challenging as it
is, but it is even more difficult with use of multiple medications across various drug classes for
treatment, given the absence of evidence of their safe use. This retrospective cohort study
assessed prescription patterns, patient characteristics associated with these patterns, risk of
adverse outcomes, and rates of readmission in women with BD who were prescribed
antipsychotic, antidepressant, or combination treatment during pregnancy, relative to untreated
women. An estimated 25% of women were prescribed psychotropic drugs during pregnancy.
Women with past suicide attempts and those with recurrence(s) during pregnancy were more
likely to be prescribed antipsychotics only, whereas women with a history of alcohol-related
disorders were less likely. Women with obesity related disorders were less likely to be prescribed
antidepressants alone in pregnancy. The number of prior psychiatric emergency department visits
was associated with use of combination antipsychotic and antidepressant therapy. This study
found no statistically significant association between type of treatments prescribed and perinatal
and psychiatric outcomes.

Keywords
bipolar disorder, pregnancy, adverse outcomes, readmission, treatment, polytherapy,
combination treatment
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Chapter 1

1

Overview

Fluctuations in mood are normal, but for patients diagnosed with bipolar disorder (BD), mood
disturbances are far more severe, exceed healthy and socially acceptable limits, and may persist
for extended periods of time. The Diagnostic and Statistical Manual of Mental Disorders, 5th
edition (DSM-5) characterizes BD by more than one manic or depressive episode separated by
periods of remission.1 Although there is no cure for BD, treatment is available to manage
relapses and alleviate mood symptoms.
BD is a chronic and episodic mental illness requiring long-term treatment, which typically
involves the use of psychotropic drugs. The number and types of medications for BD treatment
has expanded substantially over the years. In contrast to the 20th century idea that one drug,
traditionally lithium, was a sufficient treatment for patients with BD, combination therapy has
become increasingly common in clinical practice. This may be credited to the introduction of
new drug agents and the inherent complexity of BD treatment as a result of medical
comorbidities and poor effectiveness and tolerability of other available agents. Recent evidence
found that few patients receive a single psychotropic agent for their illness.2 Given the
complexity of BD and the goal of achieving and maintaining remission, multiclass treatment for
BD is common. Depending on the symptom profile of the patient, mood stabilizers,
antipsychotics, antidepressants, and anxiolytics are prescribed either alone or in combination.3
An early age of onset places women at risk of experiencing BD episodes throughout their
reproductive years.4 Prior evidence suggests that a substantial proportion of women with BD
experience recurrence episodes during pregnancy,5 and approximately one-third have a
recurrence in the postpartum period.6 Management of BD using medications is a challenge for
women who become pregnant or plan to conceive, as none of the psychotropic medications for
BD are formally approved for use during pregnancy by national drug safety organizations such
as Health Canada and the Food and Drug Administration. Due to a relatively small molecular
size and other properties that determine rates of diffusion, psychotropic medications are known
to cross the placenta at varying degrees and enter the fetal circulation in measurable quantities.7–
1
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For obvious ethical reasons, there have been no randomized controlled trials on the

medications’ safety in pregnant women. In the absence of such trials, much of the information
regarding potential risks associated with BD drugs in humans comes from observational studies.
However, the bulk of prior studies in the literature examined adverse effects of individual drugs
(in isolation), even though in clinical practice BD patients are commonly prescribed multiple
drugs across different drug classes.11
While studies have focused on complications as a result of use of specific psychotropic
medications, there are remarkably few data on the clinical profile of pregnant women with BD
who continue treatment in pregnancy, the impact of being exposed to multiple drug classes
commonly prescribed to BD patients, and the risk-benefit tradeoffs of medication use in this
population. As such, the aims of the current study were twofold: (1) to describe the
sociodemographic and clinical profiles of women with BD in Ontario who use medications
during pregnancy; and (2) to examine potential effects of the use of psychotropic drugs for BD
during pregnancy on the risk of perinatal and psychiatric outcomes.

1.1 Structure of the Thesis and Role of the Student
This thesis was prepared in accordance with The University of Western Ontario’s School of
Graduate and Postdoctoral Studies monograph format. A detailed review of the literature, along
with a critical evaluation of related studies, is presented in chapter two. Chapter three outlines
the methodological details of this thesis, and chapter four summarizes the main findings. Chapter
five is the discussion of the findings, overall strengths and limitations, as well as implications for
clinical practice and suggestions for future research. Additional appendices are provided for the
literature search strategy (Appendix A) and statement of ethics approval (Appendix B).
The candidate was responsible for all phases of the project except for the database creation. To
access the data from Institute for Clinical Evaluative Sciences (ICES), the investigator is
responsible to submit a dataset creation plan with details regarding the cohort definition,
inclusion and exclusion criteria, and all study variables of interest – this was prepared by the
candidate with input from the supervisory committee and other experts at ICES. The de-

2

identified dataset was created by ICES analysts and loaded onto a secure online portal to be
accessed by the candidate for further modifications (i.e. recoding) and analysis.
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Chapter 2

2

Literature Review

This chapter provides an overview of BD, examines the current state of knowledge related to the
study objectives, and provides background information on all study variables. A comprehensive
search strategy was conducted using multiple academic databases (details in Appendix A).

2.1 Bipolar Disorder
2.1.1 Overview
Bipolar disorder (BD), previously known as manic-depression, is classified as a mood disorder in
the DSM-5.1 The DSM is a diagnostic tool for phenomenology-based classification of mental
disorders. BD includes a spectrum of illnesses characterized by frequent recurrences of mood
episodes, leading to marked changes in a person’s mood and behavior. It is an episodic illness,
usually separated by periods of full remission or euthymia between episodes. Mood alterations in
people with BD range from an elevated, irritable, or euphoric (manic) state to sad, hopeless and
withdrawn (depressed).1 Among people with BD, mood episodes vary in frequency, duration,
and symptomatology. Diagnosis of BD requires that a patient experiences both symptomatic
poles of the illness, with at least one episode of mania in people with bipolar type I, or
hypomania (a milder form of mania) and one or more depressive episodes in people with bipolar
type II disorder.1 The requirement for mania or hypomania to be present at some point during the
course of the illness distinguishes BD from other mood disorders, namely major depressive
disorder in which patients suffer from one or more of depressive episodes without ever
experiencing an episode of mania.1

2.1.2 Clinical Picture
Depressive and manic or hypomanic states are two cardinal symptoms of BD. Manic or
hypomanic episodes are typically characterized by heightened mood, rapid speech, racing
thoughts, increased physical and mental activity levels, greater energy (with a corresponding
decreased need for sleep), irritability, perceptual acuity, heightened sexuality, and impulsivity.12
4

In hypomania, the above changes are more moderate, and generally the episode is not severe
enough to cause impaired functioning.1 In sharp contrast, depressive symptoms are characterized
by slowing of all aspects of emotion and behavior. This includes the rate of thought and speech,
energy, sexuality, and ability to experience pleasure.12 Mixed features are present in a patient
who meets the criteria for both manic and depressive episodes every day for one week. For
example, a patient may experience excitability of mania coupled with depressed mood. A
summary of the possible clinical manifestations of BD can be found in Table 2.1.
Table 2.1 Clinical manifestations of each type of bipolar disorder episode
Episode
Classification
Depression

Mania

Hypomania
Mixed
Features

Clinical Manifestations
Episode of either depressed or sad mood; lack of interest or
pleasure in doing things one previously enjoyed; changes in
eating, sleeping, or motor activity; feelings of guilt or
worthlessness; lack of concentration; and suicidal ideation or
behaviour.
Episode of elevated, or irritable mood lasting for at least 1 week
accompanied by ≥3 symptoms (of 7) for elevated/expansive mood
or irritable mood, respectively, that includes: grandiosity;
pressured speech; decreased need for sleep; racing thoughts;
distractibility; increased goal-directed activity or psychomotor
agitation; and excessive participation in pleasurable but risky
activities
Episode of at least 4 days of elevated, expansive, or irritable mood
accompanied by same symptoms described for mania
Symptoms unique to both mania and depression occur
simultaneously or within a short duration of each other, for at least
1 week

Diagnostic tests do not yet exist for BD – it is primarily diagnosed according to the clinical
history and symptoms present at assessment. At clinical assessment, BD is classified into
subtypes based on the symptomatic profile of each person. Each subtype is characterized by a
unique combination of manic and/or major depressive episodes; the current criteria are outlined
in the most recent version of the DSM (DSM-5).1 Bipolar I disorder (BD-I) is characterized by
the presence of at least one manic episode over a period of one week (or during hospitalization),
preceded or followed by hypomanic or major depressive episodes. Bipolar II disorder (BD-II) is
characterized by at least one current or past hypomanic episode, lasting a minimum of four days,
along with one or more major depressive episodes that must last at least two weeks. Diagnosis of
5

BD-I differs from BD-II by whether the patient has experienced any manic episodes in the past.
To meet the diagnostic criteria, the mood episode(s) must meet the requisite number of
symptoms outlined in DSM-5, be present most of the day- nearly every day over the specified
period of time, and bring about a noticeable change from usual behaviour or functioning. The
term BD will be used throughout this dissertation in reference to both subtypes of the illness.

2.1.3 Epidemiology
Over the last two decades, there has been an almost 50% increase in the prevalence of diagnosed
cases of BD globally.13 It is considered to be a highly disabling condition, primarily due to an
early onset and its severity and chronicity across the life span.13 The World Health Organization
(WHO) has ranked BD among the top ten most disabling illnesses in both developed and nondeveloped countries, accounting for 7% of the disability caused by mental illness worldwide.14
Although the prevalence of BD varies across countries, populations, and the definition of BD
used,15–18 recent estimates from meta-analyses range from 0.7% to 2.0%.16,19–21 In Canada, the
lifetime risk of BD is estimated at 2.2%,22 with a prevalence of 0.87% and 0.57% of BD-I and
BD-II respectively.23

2.1.4 Age of Onset
BD can appear at any age, though it typically manifests in late adolescence or early
adulthood.24,25 Data from a meta-analysis of age at onset from 15 studies yielded a weighted
mean of 22.5 years.12 It has been found that up to 60% of people with BD present with first
symptoms before the age of 21 years,12,26 which continue to recur over the person’s lifetime.

2.1.5 Sex Differences
Both males and females are susceptible to developing BD, with nearly equal ratio of illness
between the sexes.15 However, a number of studies have suggested sex differences in the
epidemiology, comorbidity patterns, and symptom profile of patients with BD. A recent
systematic review summarizing evidence from the literature described key differences. The
majority of the studies report an increased risk of BD-II among women.27 Higher prevalence
rates of BD-II was subsequently reported by Merikangas and colleagues in a large population6

based study involving 11 countries.28 Additionally, the review found alcohol-use disorders to be
a common problem among men with BD, whereas eating disorders and post-traumatic stress
disorder were more common among women. The likelihood of experiencing mixed episodes and
rapid cycling of the illness was also found to be significantly greater for women than for men.
Although this review did not find the number of depressive episodes and time spent in
depression to differ between the sexes,27 more recent studies do show that women tend to have
more depressive symptoms and maintain a predominately depressive polarity of illness.29–31

2.2 Etiology of Bipolar Disorder
A multifactorial model is currently thought to be involved in the development of BD,32 but the
precise mechanism underlying its etiology is not yet well understood. Research suggests that BD
is caused by biological predisposition, in combination with social, environmental, and
neurological risk factors.

2.2.1 Neurological Factors
Early research explains BD to be the result of chemical imbalances in the human brain. It is
hypothesized that changes in the levels of neurotransmitters such as norepinephrine, dopamine,
and serotonin are key in the pathophysiology of BD. Current pharmacological treatments
function to modify levels of these neurotransmitters. Dopamine is a neurotransmitter that is
widely known to help enhance mood. It is found at higher levels in BD patients in a manic phase
and lower levels during a depressive phase.33 A deficiency in serotonin levels has been observed
in depressive and euthymic states, suggesting a lower serotonin receptor activity in BD
patients.34 BD has also been linked to dysfunction of the hypothalamic-pituitary-adrenal (HPA)
axis, a pathway in the brain thought to be involved mood regulation.35

2.2.2 Genetic Factors
There is particularly strong evidence from studies that suggests BD is a heritable illness with
genetic underpinnings. Several epidemiological, family, adoption, and twin studies have been
published in an attempt to disentangle environmental and genetic influences that can predispose
people to BD.36 One review summarized familial studies and found consistently excess risks
7

among first-degree relatives of BD patients compared with relatives of non-psychiatrically ill
groups, 37 particularly among those with early-onset BD.38,39 This suggests that the illness
aggregates in families and provided some support for the role of genes in the underlying
etiology. Twin studies help establish the role of genetic heritability, the interplay of genes with
the environment, and estimate their magnitude of influence.36 Studies have reported higher BD
concordance among monozygotic twins (who are genetically identical) compared to dizygotic
twins (who share on average half of the genes), providing very compelling evidence for the BD
gene hypothesis.40–43 However, the concordance rates of BD among twins was not 100%,
demonstrating that genes alone are not sufficient to cause illness. Today, the etiology BD is best
explained by the interaction between genes or complex genetic mechanisms, together with
environmental non-genetic and stochastic factors.44

2.2.3 Social and Environmental Factors
Given that having a relative with BD does not guarantee that one will develop the illness
suggests that other factors play a role in the onset, course, and expression of BD. This is
supported by a growing body of evidence that the biological vulnerabilities of BD can remain
dormant until triggered by environmental stressors.45 Major life stressors have the ability to
increase the likelihood of a recurrence of mania or depression in people with BD. These life
changes can be positive or negative, for example the death of a loved one or a job promotion.
Additionally, social support from significant others has been found to predict a more positive
course of illness compared to no support.46

2.3 Bipolar Disorder and Pregnancy
Though no Canadian data exist for the antenatal prevalence of BD, recently published data from
the UK found a population prevalence of 0.3% for BD-I and BD-II.47 Pre-existing BD has been
associated with higher risks of obstetrical complications compared to women with no history of
mental illness or those who developed BD after the index birth,48 suggesting that having the
disorder, irrespective of treatment status, may be associated with poor birth outcomes. Jablensky
and colleagues compared women with BD and women without psychiatric disorder to ascertain
the incidence of complications that occur during pregnancy and delivery. They found a higher
8

incidence of obstetrical complications in women with BD, which included antepartum
hemorrhage and placental previa.48 Furthermore, women with BD were more likely to have
gestational hypertension and to give birth to preterm, low birth weight, and small for gestational
age babies.49,50 Only one study found no association with gestational diabetes, suggesting no
difference in rates of gestational diabetes between women with and without BD.49 Though these
studies highlighted that women with BD are at a higher risk of adverse birth outcomes, they did
not adjust for treatment status, making it difficult to determine whether it was the illness itself or
treatment use that lead to the complications.

2.4 Pharmacological Treatment
2.4.1 Pharmacological Treatment for Bipolar Disorder
The primary goal of psychotropic treatment for BD is twofold – acute stabilization and
maintenance. Acute treatment aims to stabilize symptom exacerbations and allow the return to
pre-morbid level of psychosocial functioning, whereas the goals of maintenance treatment are
relapse prevention, reduction of subthreshold symptoms, and to maximize functioning in all
important life domains.1 A review found that with treatment, 19%-25% of patients with BD will
experience a recurrence every year, compared to 23%-40% of those on placebo.51 If left
untreated, patients can experience more than ten episodes of full-fledged mania or depression
during their lifetime.52 The lifetime recurrence risk of an affective episode is as high as 90% in
people who reported a single manic episode, and more than half of patients (60%) will
experience recurrence of BD in the first two years of the illness.53 Moreover, despite continual
treatment, survival analyses from one study found a five year recurrence risk of 73% in BD
patients following initial diagnosis.53 As such, long-term or maintenance treatment becomes a
necessity for most patients. Without treatment, BD episodes can become more frequent and
severe, interfering with daily life and taking longer to subside.54,55 Untreated patients are also at
risk of increased morbidity, such as increased rates of suicidal behavior and increased
employment problems and higher social costs (loss of friends and contacts).56,57 Persistent
unresolved symptoms and a long duration of untreated symptoms can lead to treatment resistance
in patients. In BD patients, one study found that patients in the early stage of illness who had less
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than 5 previous episodes were 40% more likely to respond to treatment compared to those with
more than 10 prior episodes.58
Treatment of BD includes psychotropic medications and psychosocial treatments
(psychotherapy, rehabilitation), though medication is considered to be the cornerstone.
Psychotropic medication, used for both acute exacerbations and long-term maintenance
treatment, can be further categorized into primary and adjunct medications. Mood stabilizer
medications are considered the primary treatment for BD, and help reduce swings in abnormal
moods and prevent future recurrences. Adjunct medications include drugs classified as
antidepressants, anxiolytics, and antipsychotics, which are commonly used for the short term to
treat specific symptoms that may occur in a particular phase of the illness, if the patient is
unresponsive to the standard treatment, or if there is a need for quick response.59 The list of
medications in each group is detailed in Appendix C. In Canada, the first-line of treatment for
acute mania consists of mood stabilizers and several atypical antipsychotic agents, whereas firstline options for management of bipolar depression include mood stabilizers and atypical
antipsychotic medications either alone or combined with adjunctive use of antidepressant therapy
as the second-line option.3

2.4.2 Mood stabilizer Medications
Mood stabilizers are not a formally recognized therapeutic drug class.3 As defined by Bauer and
Mitchener (2004),60 medications referred to as mood stabilizers are those that show evidence of
short-term efficacy for both poles of BD, where it can be used for treatment and maintenance of
relief from acute manic or depressive symptoms. To date, lithium is the only drug that has been
shown to be effective in treating all types of BD episodes. However often drugs from different
therapeutic classes are prescribed, in place of or in addition to mood stabilizers. One such class is
anticonvulsants; certain medications are approved for use for BD given its mood stabilizing
properties. These drugs include carbamazepine, valproate, and lamotrigine. Studies have
highlighted their efficacy in both acute and maintenance treatment of BD.61,62 Newport and
colleagues found the risk of recurrence to be 3.3 times lower in lamotrigine-treated patients
compared to patients who opted to discontinue psychotropic treatment during pregnancy.63
Evidence from placebo controlled trials support lithium's prophylactic effects on relapses, for
10

which the evidence far exceeds that of other agents. Additionally, there is substantial evidence of
long-term reduction in suicide risk with the use of lithium.64–67 There are drawbacks to lithium
therapy which include a narrow therapeutic index, the need for regular monitoring of patient's
plasma concentrations, and poor tolerability.68 Despite this, lithium remains the gold standard for
treatment of BD. For the purpose of this thesis, lithium was grouped with anticonvulsants to be
collectively referred to as mood stabilizers, which is consistent with previous studies.69–72

2.4.3 Antipsychotic Medications
Antipsychotics are fast-acting anti-manic agents that also help control psychotic symptoms, such
as hallucinations or delusions. They are used in BD treatment for both acute and maintenance
phases of the treatment.3 There are two types, typical and atypical antipsychotics. Typical, or
first generation antipsychotics (FGA) were first developed in the 1950s, whereas atypical or
second generation antipsychotics (SGA) were approved for use in the 1990s. Atypical
antipsychotics are used more frequently because they produce less severe neurological sideeffects compared to typical antipsychotics.73,74 Among BD patients, the efficacy of antipsychotic
treatment is well established.75–77

2.4.4 Antidepressant Medications
There has been a marked increase in antidepressant use over the last 10 years, and recent
prevalence data suggests an increase of over 8% in North America alone.78 Among BD patients,
prescription data from the US show that 30% of all treatment regimens include antidepressants.79
Tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs) were first
introduced in the 1950s and are classified as first generation antidepressants, selective serotonin
reuptake inhibitors (SSRIs) were introduced in the 1980s as second generation antidepressants,
and serotonin-noradrenaline reuptake inhibitor (SNRIs) were introduced during the 1990s and
are referred as third generation antidepressants. Among all antidepressants, SSRIs are commonly
used for treatment of depression in patients with BD.
There are numerous studies that have examined the efficacy of antidepressants, although there
are inconsistencies in the literature. Some studies suggested an improvement in depressive
symptoms with the use of antidepressants,80 while others do not support their role in BD
11

treatment.81,82 One meta-analysis evaluated the efficacy of up to 16 weeks of antidepressant
adjunct treatment in adult patients in the depressive phase of BD, and the findings suggested that
augmentation with antidepressants provided no significant benefits over placebo with respect to
response and remission rates. 83 Moreover, use of antidepressants for BD treatment has become a
contentious topic, as emerging evidence suggests that use of antidepressants can induce a switch
to manic or hypomanic episodes, particularly among females, patients diagnosed with BD-I, and
patients on tricyclic antidepressants.84,85 The risk of switch reported by Viktorin and colleagues
did not remain in patients treated with both antidepressants and mood stabilizers.84 Another study
found that switch rates are reduced if mood stabilizers and antidepressants are used concurrently
(31.6% compared to 84.2%).81 As a result, international and Canadian guidelines recommend
conservative and short-term use of antidepressants in BD-I patients, and avoiding monotherapy
completely for BD depression.3,86 However, the evidence regarding the risks of antidepressant
monotherapy is still debated in the literature.83,85,87

2.4.5 Antianxiety Medications
Epidemiologic studies have established that there is a high prevalence of comorbid anxiety
disorders and insomnia in BD patients.55,88–90 Comorbid anxiety is also independently associated
with greater disability and severity of BD.91 Thus, antianxiety medications, or anxiolytics, are
often prescribed to provide sedative effects. Benzodiazepines are one group of antianxiety
medications most commonly prescribed in BD treatment, with a five-year prevalence of use
ranging from 58% to 75% in people with BD.92 Though they are not the core treatment for
mania, they are adjuncts to mood stabilizers to help provide sedative effects for agitated or
aggressive behaviour and improve sleep. The safety of prescribing benzodiazepines has been
debated given that benzodiazepines are controlled substances with addictive and abuse potential.
Given that substance use disorder is a major comorbidity in BD patients,93 treatment with
benzodiazepine can result in its misuse.94 Additionally, benzodiazepines have been reported to be
associated with a higher risk of mood episode recurrence in BD patients.95 In general,
benzodiazepines are not recommended to be prescribed as monotherapy,96 and clinicians are
encouraged to prescribe the lowest possible dose for a short period of time.3
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2.4.6 Multiclass Treatment for Bipolar Disorder
Few drug trials or observational studies have assessed various combinations of drug regimens for
BD treatment. One randomized trial compared the time to recurrence between patients on
quetiapine (atypical antipsychotic) with lithium or divalproex (anticonvulsant) and placebo with
lithium or divalproex. They found that adding quetiapine to the treatment regimen was associated
with a statistically significantly longer time to relapse of a mood episode.97 Similarly, another
trial looked at quetiapine combined with lithium or divalproex to assess efficacy in treating BD
mania. Combination psychotropic treatment was found to be more effective in treating mania
compared to monotherapy.98 There are more such trials; however, like the ones described,
controlled studies have most often examined the effects of particular drugs alone, and the effects
of concomitant drug use for BD were not addressed. One study examined the addition of
antidepressants as an adjunct treatment to mood stabilizers.82 The study revealed no evidence
that treatment with a mood stabilizer and an antidepressant conferred a benefit over treatment
with mood stabilizer monotherapy. Although this study did not look at the effects of a singular
drug, it is important to note that the list of medications grouped under the drug classes was not
comprehensive. The antidepressant category included only two drugs, bupropion or paroxetine,
while mood stabilizers included lithium, valproate, carbamazepine, or other undisclosed Federal
Drug Agency (FDA) approved antimanic agents. One cross-sectional study by Gazalle and
colleagues found a positive association between number of suicide attempts and polypharmacy in
BD patients, potentially suggesting that the use of multiple medications concurrently may be
associated with severity of BD illness and suicidality.99

2.5 Treatment Recommendations for Pregnant Women
Many women with severe mental illness are also mothers, although less frequently than the
general population.100 All psychotropic medications can readily pass through the placenta, and
none have been approved by the drug control agencies for use during pregnancy, as double-blind
placebo controlled trials have not been conducted in pregnant BD patients. Recurrences occur in
45% to 50% of all pregnancies,101 and one study found that with treatment, 19%-25% of BD
patients overall will experience a recurrence every year, compared to 23%-40% of those on
placebo.51 Lack of control over these episodes may put both the woman and the fetus at risk,
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especially given that BD episodes are associated with an increased risk of alcohol and substance
use, poor nutrition, smoking, and suicide.12 Due to the potential for risk to the fetus, women with
BD who are pregnant may discontinue use of medication. One study found that not only is the
risk of recurrence twofold among women who discontinue mood stabilizers during pregnancy
when compared to women who continue treatment, but also that more than 40% of the pregnancy
period is spent in an episode of BD.102
Management of BD with treatment during pregnancy is complex for both the physician and
patient involved and requires an informed decision about what constitutes reasonable risk. There
are no hard and fast rules for treatment as there are individual variations in risks and benefits of
medication use. Treatment recommendations depend on a patient’s previous and current mental
health status.96,103 Ideally, a BD patient would consult with their healthcare providers regarding
pregnancy and develop a management plan before conception. However, this is complicated
because many pregnancies among patients with BD are unplanned.104 In Canada, the use of
psychotropic medications during pregnancy is recommended if necessary, with a preference for
monotherapy, use of the minimum effective dose, and close monitoring of serum levels and
adjustments of dosages.96,105 Patients who are mostly asymptomatic and are at low risk of relapse
can consider tapering mood stabilizer prior to conception. Signs of relapse must be closely
monitored. Patients at high risk of relapse are recommended to use mood stabilizers in varying
doses both during and after pregnancy. The safety profile for most psychotropic drug use in
pregnancy is not clear, although attempts have been made to quantify the risks.

2.6 Bipolar Disorder Treatment in Pregnancy and Birth
Outcomes
2.6.1 Systematic Search Strategy
We used a systematic search strategy to identify relevant articles from Medline-Ovid, Embase,
CINAHL, and PsycINFO (inception to September 2017). We developed a search strategy in
consultation with a professional librarian and adapted it for use in each database. The purpose of
the literature search was to identify prior studies that examined adverse maternal, neonatal,
labour or delivery, and psychiatric outcomes of treatment with psychotropic medications for BD
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during pregnancy. The search strategy was derived using three main concepts – bipolar disorder,
pregnancy, and treatment with psychotropic medications – along with their respective keywords
(Appendix A). All identified studies were imported into Covidence software and underwent
screening. Studies were included if the full-text was in English and they discussed the impact of
treatment specifically among women with BD during pregnancy. We excluded qualitative review
articles and case-studies.

2.6.2 Mood stabilizers and Anticonvulsants
There is evidence that some mood stabilizers have teratogenic potential, and the risks have been
reported in depth in the literature.106–108 Among the mood stabilizers and anticonvulsants, the
reproductive safety risks are best understood for lithium, valproate (valproic acid or sodium
valproate), carbamazepine, and lamotrigine. Lithium is considered the gold standard treatment
for BD given its long track record of efficacy, and it remains the first-choice agent to manage
mood episodes.96 However, lithium has traditionally been considered to be teratogenic due to a
strong association between lithium and Ebstein’s anomaly, first reported in the early 1970s.109,110
Subsequent studies have since provided conflicting data about the degree of risk associated with
maternal lithium use and found that the previous risk was overestimated. Ebstein’s anomaly is
rather rare in the general population, recently estimated at 0.18 per 100 infants, but its prevalence
in babies born to women exposed to lithium in the first trimester was also found to be
considerably low at 0.60 per 100 live births among infants exposed to lithium,111 suggesting that
it can be used in pregnancy with caution among women for whom other drugs are ineffective,
where the drugs with a more favorable risk profile are unsuitable, or when the risk of recurrence
may overshadow the small risk of Ebstein’s anomaly. More recent evidence has also suggested
an increased risk of fetal cardiovascular anomalies in lithium-exposed pregnancies compared to
nonteratogenic exposure.112
Of particular concern is valproate, an anticonvulsant mood stabilizer that is associated with a
high rate of congenital malformations among infants exposed in utero in first trimester.106 One
meta-analyses, including more than 60,000 women on valproate monotherapy, reported an
overall malformation rate of 17.6%.113 These malformations include neural tube defects, effects
on cognition and brain volume, craniofacial anomalies, cardiac defects, cleft palate, and
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hypospadias. Additionally, valproate has been linked to neurodevelopmental disorders, with
autism being the most frequent diagnosis.114 Similarly, intake of the anticonvulsant mood
stabilizer carbamazepine in the first trimester has also shown increased risk of fetal anomalies,107
though at a comparatively lower rate of 2.2-2.3% and with no evidence of intellectual
impairments.106,107.
In contrast, Lamotrigine is considered to be a safer alternative to other anticonvulsants given the
evidence of comparatively lower rates of congenital anomalies. However, there remains some
uncertainty regarding its safety profile. For example, lamotrigine has been linked to oral cleft
defects;115 however, aggregate studies and a meta-analyses contradict this association.106,116
Holmes and Hernandez-Diaz (2012) reviewed the literature on other anticonvulsants, specifically
topiramate and gabapentin.117 They found that although the number of studies is limited, there is
evidence that topiramate exposed pregnancies are at risk of teratogenicity.117 Information on
gabapentin was not sufficient to determine teratogenicity. A more recent prospective study on
gabapentin by Fujii and colleagues (2013) found no increased risk of malformations, but found
higher rates of preterm birth, low birth weight, and admission to neonatal intensive care.118
Literature on the effects of other anticonvulsants in a pregnant BD population is scant.

2.6.3 Antipsychotics
There has been a considerable rise in the use of antipsychotics over the years, and they are
prescribed to approximately 0.2-0.3% of all pregnant women.119 There are two types, typical and
atypical antipsychotics. The consensus on the use of antipsychotics is that there is little
difference in perinatal risks between first generation antipsychotics and second generation
antipsychotics;120 both have limited teratogenic potential and pose minimal risk with regards to
major congenital malformations.106,121 However, the risk of adverse outcomes cannot be
completely ruled out given that FGAs have been associated with increased risk of premature
delivery and exposure in the third trimester has been linked to transient extrapyramidal
symptoms and withdrawal symptoms. Even though certain first generation antipsychotics are still
widely used, second generation antipsychotics are favoured in practice owing to fewer sideeffects. They are also the focus of more recent research on antipsychotics, though they have not
been extensively studied and data on safety is scarce. Early research comparing exposed women
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with healthy unexposed women report a moderate increase in risk of adverse maternal and infant
outcomes.120 However, more recent studies comparing exposed women to those with existing
psychiatric illness but unexposed to SGAs report few associations between antipsychotics and
adverse birth outcomes.120 One study, conducted by Vigod and colleagues, used propensity score
methodology to minimize confounding bias and compare two groups of women who are similar
with respect to their mental health and medical history, with the main difference being the
antipsychotic treatment exposure. Their results confirmed that antipsychotic use in pregnancy
posed a minimal risk of adverse outcomes, as antipsychotic users were not at a substantially
higher risk of maternal and perinatal outcomes that included gestational diabetes, hypertensive
disorders of pregnancy, venous thromboembolism, preterm birth, and a birth weight of 3rd or
97th centile compared to non-users.122 They did, however, report higher rates of hypertensive
disorders, venous thromboembolism, preterm birth, and neonatal mortality in antipsychotic users
compared to the general population. As a result, the authors suggest that patients prescribed
antipsychotics in pregnancy should be carefully monitored.

2.6.4 Antidepressants
A majority of the studies that evaluated safety of antidepressants in early pregnancy do not
indicate an enhanced risk of congenital malformations,123–126 but there remains much variation
between results reported in the literature.127–132 Studies have also linked antidepressants to other
adverse outcomes, such as low birth weight and preterm birth in neonates,133–137 but some studies
did not report this relationship and instead found either a non-statistically significant association
or a significantly lower risk.126,138 Additionally, one review found that women who used
antidepressants during pregnancy had an increased risk of gestational hypertension,
preeclampsia, and delivery complications including placental abruption, premature rupture of
membranes, need for labor induction or Caesarean section, and postpartum hemorrhage. The
risks increased when medication was consumed later in pregnancy or throughout pregnancy, and
was slightly higher for serotonin-noradrenaline reuptake inhibitors and tricyclics when compared
to SSRIs.139 Recently, antidepressant use in pregnancy has also been linked to the development
of autism spectrum disorders in children.140–143 However, the results of the observational studies
have been inconsistent.144,145 Brown et al. conducted a population-based study assessing the risk
of autism disorder with in utero exposure to antidepressant compared to unexposed children.
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Two methods of analyses were used to control confounding: multivariable regression-adjusted
analyses and an inverse-probability-of-treatment weighting. Both the crude and multivariableregression analyses showed statistically significant associations, but the inverse-probability-oftreatment-weighted analyses did not. It is important to note that that the effect estimate was
borderline (95% CI, 0.997-2.59), which one can argue is too close to conclude there is no
increased risk. A number of meta-analyses have been conducted in an effort to reconcile the
findings of various studies and come to consensus.146–150 One review was conducted to reconcile
disparate findings across several meta-analyses and found that the findings across these studies
have been mostly consistent, suggesting an increased risk of autism in the offspring from
antidepressant exposure during pregnancy. The risk decreased after adjusting for confounding
factors, and for the most part is no longer statistically significant after adjusting for maternal
mental illness.151

2.6.5 Antianxiety Medications
Several studies have reported a statistically significant association between use of
benzodiazepines and certain pregnancy outcomes. Risk of major congenital malformations tends
to be low,152–154 however poor neonatal outcomes are evident. Benzodiazepine treatment has
been recently linked to increased risk of cesarean delivery, low birth weight of baby, and
increased use of ventilator support for the newborn.155 Prolonged use of benzodiazepines,
particularly during late pregnancy or during labor, has been associated with neonatal effects and
withdrawal symptoms including poor suckling, hypotonia (floppy infant syndrome), and
respiratory distress.106 However, it is important to also consider that the risk of untreated anxiety
and insomnia in pregnancy can potentially trigger recurrences, and may lead to physiologic
effects, including reduced level of self-care, worsening mood, and impaired functioning.106

2.7 Polytherapy During Pregnancy
2.7.1 Prescription Patterns
Given the complexity of BD, the use of multiple treatments is very common in clinical practice,
an approach commonly referred to as "rational polypharmacy".156 In the overall BD population,
studies examining the drug utilization patterns have found that the rates of prescription for
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monotherapy and polytherapy are quite similar.79,157 To our knowledge, only one study described
the prescription patterns of concomitant treatments in BD patients during the period of
pregnancy.158 In their sample of 197 patients treated during pregnancy, 74 (37.6%) patients were
using combination therapy, while 85 (43.1%) were on a monotherapy regimen.158
Antidepressants were most frequently used in this population, either as monotherapy or
combined with other psychotropic medications.

2.7.2 Treatment and Pregnancy
Little is known regarding the combined effects of multiclass polypharmacy among pregnant
women with BD, although there are studies that have assessed polypharmacy in non-BD
pregnant populations. One population-based cohort study examined neonatal morbidity as a
result of use of SSRI antidepressants combined with other drug classes known to act on the
central nervous system, and whether the combined use imposes a larger harm than their use
alone.159 They found an increased risk of neonatal morbidity for most drug groups when used
alone, and a stronger effect on when combined with SSRIs. However, the authors did
acknowledge that confounding by indication cannot be ruled out.
Another study investigated pregnancy, delivery, and neonatal outcomes in patients prescribed
atypical antipsychotic monotherapy and polytherapy with other classes of psychotropic
medications.160 The findings suggest that polytherapy was associated with a higher risk of
adverse pregnancy outcomes, compared with monotherapy. The polytherapy group had higher
use of instrumental deliveries, and a greater proportion of neonates who were large for
gestational age, born premature, transferred to a neonatal intensive care unit, present with poor
neonatal adaption signs, and had congenital malformations.160 It is important to consider the
limitations of this study. Given the small sample size (n=133) of exposed women, the analysis
was conducted without adjusting for key confounders. Additionally, confounding by indication
was not addressed.
Lastly, one Swedish study by Boden and colleagues investigated risk of adverse birth outcomes
in women who are diagnosed with BD and treated with medication during pregnancy.161 Patients
were classified as being treated if they were received lithium, antipsychotic drugs (except for
prochlorperazine, levomepromazine, and melperone), or any of the anticonvulsants
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carbamazepine, lamotrigine, and valproate. Treated and untreated groups were compared to a
third group of all women in the population who gave birth with no diagnosis of BD who were not
prescribed psychotropic treatment. The study concluded that women with BD, irrespective of
their treatment status, had a higher risk of adverse pregnancy outcomes.161 This is suggesting that
illness itself was contributing to the increase in risk of adverse outcomes. It is important to note
that BD patients are often prescribed antidepressants in addition to mood stabilizers and
antipsychotics. This study failed to control for the confounding effects of antidepressant
medications, despite the evidence of antidepressants playing a role in adverse birth outcomes. It
is clear that there still remains much uncertainty about the safety of multiple treatment use during
pregnancy in patients diagnosed with BD.

2.8

Knowledge Gap

It is important to recognize that although published guidelines are available for BD treatments in
pregnancy, recommendations are primarily based on monotherapy and/or drug-specific studies.
Though monotherapy is most common, we know that it is not the only type of treatment in
patients with BD, and in many cases, given that current pharmacological treatment is symptombased, polytherapy is common.162 Physicians are advised to make every effort to keep the
number of medications and dosages to a minimum; however, exposure to medications from more
than one drug class may be unavoidable in some cases. The use of adjunct medications in BD
patients is further supported by empirical evidence of superior efficacy from use of certain
combination therapies compared to monotherapy.77,163–165 Most recently, Broeks and colleagues
found that in their sample of patients, 50% of women were on a polytherapy regimen during
pregnancy,158 confirming that polypharmacy is frequent during the pregnancy period. As
highlighted in this chapter, drug trials of particular psychotropic agents have reported teratogenic
risks in BD patients, which is why many are not recommended for use in pregnant women. Upon
review of the literature, we found that controlled studies on the use of combination psychotropic
medication in pregnancy for BD have been uncommon. Other studies have reported a higher risk
of adverse pregnancy outcomes as a result of psychotropic treatment use in pregnancy in a nonBD population. However, it is important to compare treatment effects among women with BD
given that higher risks of adverse outcomes have also been reported in untreated BD patients.
Whether the risks are compounded, decrease, or remain unaffected by treatment in pregnancy is
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still unclear. Therefore, increased attention to the study of combinations of modern BD
treatments in pregnancy is required to determine the most efficacious and safe combinations.

2.9 Summary and Rationale
Pregnancy is a thrilling and joyous occasion for most, but for those suffering from BD, it can be
a distressing experience. With an age of onset precisely overlapping with the time when most
women are in their reproductive years, it raises the likelihood of considerable burden of BD
during pregnancy. For serious mental illnesses such as BD, psychotropic medications are
essential to allow a person to maintain or revert to normal level of functioning. However, the
treatment decision-making process can be a ‘minefield’ and is seldom free of risks. The decision
to use medications during pregnancy raises a number of difficult ethical and medical issues,
which are made more challenging by the lack of adequate information regarding safety. One
qualitative study evaluated the real world decision-making process for antipsychotics and mood
stabilizers during pregnancy – the findings suggest that due to the lack of sound evidence for
clinicians to base their recommendations on, most women had to rely on their best judgment and
take a guarded risk with their treatment decisions.166 Others may entirely avoid treatment, and
untreated symptoms carry substantial risks,167 increasing likelihood of relapse and compromising
antenatal care. Thus, women with BD are at a disadvantage when managing their pregnancies, as
they may receive either no pharmacotherapy, or pharmacotherapy that is not entirely evidencebased.
Primum non nocere (first, do no harm) is a guiding principle for all physicians, where the
patient’s well-being is always the primary consideration regardless of the intervention or
procedure introduced. Rational use of psychotropic drugs entails improving one's quality of life
and functional status while minimizing adverse effects. Among BD patients, medication
regimens often involve use of concomitant medications from different therapeutic drug classes,
which include mood stabilizers, antipsychotics, antidepressants, and anxiolytics. However, as
described in this chapter, current safety guidelines do not reflect polytherapy treatment use.
There is insufficient guidance for clinicians to deliver evidence-based advice on multiple
medication use to expectant mothers with BD, and the clinical guidelines reflect the paucity of
available literature on the effects of polytherapy for BD. Additionally, evidence has shown that
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women with BD exhibit higher rates of unplanned pregnancies,168 which can inadvertently
increase the risks. Given the high risk period and lack of relevant studies, further research is
needed to understand the safety of medication use in pregnant women with BD.

2.10 Objectives
Our initial objective was to examine the impact of mood stabilizer medications, accounting for
interclass polypharmacy, during pregnancy on adverse birth outcomes among women with BD.
After obtaining our study cohort, we found that we did not have sufficient numbers to include all
drug classes as part of our objectives. Therefore, we have focused on the three most frequently
used combinations of treatments from our dataset – specifically antipsychotics, antidepressants,
and combined therapy with both antipsychotics and antidepressants.
Our study objectives were:
1. To describe the patterns of mood stabilizer, antipsychotic, antidepressant, and anxiolytic
prescriptions during pregnancy over a period of 12 years (2002-2014) in women aged 13
to 50 years who are diagnosed with bipolar disorder in Ontario.
2. To identify the factors associated with use of antipsychotics, antidepressants, and
antipsychotic-antidepressant polytherapy in pregnant women diagnosed with bipolar
disorder.
3. To assess the impact of antipsychotics, antidepressants, and antipsychotic-antidepressant
polytherapy on the risk of maternal, neonatal, and labour and delivery outcomes in
women with bipolar disorder.
4. To assess the impact of antipsychotics, antidepressants, antipsychotic-antidepressant
polytherapy on psychiatric readmission rates during the early postpartum period in
women with bipolar disorder.
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Chapter 3

3

Methods

This section outlines the methods applied to our secondary analysis of health administrative data.
Ethics approval was obtained from the Research Ethics Board (REB) at Western University
(Appendix B).

3.1 Study Design and Setting
We conducted a retrospective cohort study using data from April 2002 to March 2014. We used
the linked healthcare administrative databases from Ontario housed at ICES. Data on physician
billings, hospitalizations, and prescription drug use for a subset of the population within the
province of Ontario were obtained.

3.2 Data Sources
ICES is an independent, non-profit research organization that maintains population-level data for
the purposes of research on healthcare, generated from publicly funded healthcare services
covered under the Ontario Health Insurance Plan (OHIP). As a prescribed entity under the
Personal Health Information Protection Act (PHIPA), ICES data is an inventory of secure and
accessible linked health administrative databases for the entire province of Ontario, Canada
(population of approximately 13 million). Individual ICES data is de-identified using an
encrypted common identifier or “code” that is specific to each person in the database and is used
to link multiple health administrative data to ensure privacy and confidentiality. The databases
described below were accessed for cohort definition, exposure and outcome ascertainment, and
covariate specification. Diagnoses in these datasets are recorded using the Canadian Coding
Standards for the International Statistical Classification of Diseases and Related Health Problems
(hospital) and physician billing claim codes (OHIP).

Canadian Institute for Health Information (CIHI) Discharge Abstract Database (DAD):
The CIHI-DAD contains data that is abstracted from hospital records, where each record
corresponds to a single hospitalization. It includes patient-level data, administrative, and clinical
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data for hospital discharges (acute and chronic care inpatient, day surgery, and rehabilitation) in
Ontario. Information captured includes diagnosis, procedure, and treatment information.
Diagnostic codes are classified using the Canadian version of the International Classification of
Diseases and Related Health Problems, 10th revision, (ICD-10-CA) and procedure codes are
assigned using Canadian Classification of Health Interventions codes (CCI). Information from
this data source has been validated, and with a few exceptions in the type of diagnosis, most
procedures are found to be complete and reliable, with a high degree of accuracy, sensitivity, and
an almost perfect specificity.169

Ontario Mental Health Reporting System (OMHRS) database: This database contains
information on adult inpatient psychiatric admissions to a designated mental health bed in
Ontario from 2005 onward. It includes detailed information about mental and physical health,
social support, and service use. Prior to 2005, this data was captured by CIHI-DAD. Diagnoses
are assigned using DSM-IV classification system.

MOMBABY database: The MOMBABY database is an ICES-created dataset derived from
CIHI-DAD that deterministically pairs the inpatient hospital records of delivering mothers with
their newborns. This database contains information on 98% of all hospital deliveries in Ontario
and was used to identify the obstetric deliveries in this study.170 Each record represents a
mother-baby pair and contains additional information including maternal age, newborn birth date
and gestational age, and indicators for stillbirths and multiple births. The MOMBABY dataset is
derived and validated for use by ICES.

Ontario Drug Benefit (ODB) database: The ODB database stores records of all dispense
outpatient medication prescriptions paid for by the provincial government. This database has a
high level of accuracy (overall error rate of less than 1%).171 Eligibility for drug coverage under
ODB includes unemployment, disability, high prescription drug costs relative to net household
income, and recipient of home care services. We limited our sample to people covered by ODB
and used this database’s prescription drug information to define the exposure status.
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Ontario’s Registered Persons Database (RPDB): The RPDB of the Ontario Ministry of Health
and Long-Term Care is a population-based registry that provides information about all people
who are eligible for health coverage under OHIP. The database maintains information on a
number of patient demographic characteristics. For our purposes, we used RPDB to obtain data
on patient age (categorized into 4 groups) and income (categorized into groups based on quintiles
of average neighbourhood income).

Ontario Health Insurance Plan (OHIP) Database: The OHIP database stores information on all
claims made by clinicians for insured inpatient and outpatient services provided to the residents
of Ontario. Most physicians bill their services to the province and submit claims for
reimbursement. Each record in the database represents a service rendered to a specific person, on
a specific day. For this study, OHIP claims were used to identify treatment history and outcome
variables.

The National Ambulatory Care Reporting System (NACRS): This database contains information
on visits to hospitals and community-based ambulatory care facilities. Encounters captured
include day surgery, some hospital-based outpatient clinic visits (i.e. dialysis clinic), and
emergency department visits.

3.3 Cohort Definition
Our cohort consisted of women with BD, hospitalized for a singleton obstetrical delivery, with a
conception date between the fiscal years 2002 and 2014. The conception date defined the date of
cohort entry. It was derived by subtracting the gestational age at delivery from the baby’s date of
birth. In the case where the baby’s birth date was missing, the mother’s admission date to the
hospital was used as delivery date. In the case where the mother’s admission date was missing,
discharge date was used for delivery date.

WHO considers women between the ages of 15 and 49 as those within reproductive age. To
minimize the possibility of exclusions during cohort creation, we expanded the age range from
13 to 50. Canadian data suggest that few women (<0.1%) ages 45 and above give birth.172
Women were included in our study cohort if they met at least one of the following criteria: (i) an
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inpatient hospitalization with a primary discharge diagnosis of BD any time prior to the index
pregnancy; (ii) an outpatient OHIP fee code for a mood disorder plus a prescription of a mood
stabilizer prior to the index pregnancy (note that the outpatient OHIP fee code (296) without a
prescription would not have been sufficient to identify BD patients because the fee code is used
concurrently used for diagnosis of unipolar depression). Additionally, women were included in
the study cohort if they were continuously covered for ODB throughout their pregnancy, defined
as having filled any provincially funded drug prescription within six months prior to conception
and another either during their pregnancy or within six months after delivery.

After identifying data on all records of singleton deliveries between 2002 and 2014, we excluded
observations with missing or invalid maternal IKN numbers. Additional exclusions included: (1)
women with gestational weeks less than 20 and more than 45 at delivery; (2) pregnancies with
multiple overlapping records over the study time period; (3) any data with inconsistencies and
duplicate records for pregnancy; (4) any woman sharing the newborn's IKN, given that we would
be unable to differentiate between the two persons; (5) observations with missing birth date for
the baby and the time period between the mother's admission and discharge date greater than 14
days (since we were unable to determine the conception date for these women; and (6) women
who filled a treatment prescription up to 30 days prior to pregnancy and none during the period
of pregnancy. This was done to ensure that all women who may have been exposed to
medications close to conception were not misclassified into the non-prescription group, avoiding
any treatment influence from early exposure.

3.4 Variable Definitions
The variables were either directly selected from the ICES databases or were derived using a
combination of standard classification codes or existing variables from ICES databases. For a
complete list of study variables, definitions, data sources, and formats, please see Appendix D
and E.
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3.4.1 Ascertainment of Exposure
Exposure status was dependent on whether a woman was using psychotropic treatment during
the period of pregnancy. A woman would have been considered to be an exposed case if she was
using one or more medications across the therapeutic drug classes: mood stabilizers,
antipsychotics, antidepressants, and anxiolytics. For a complete list of all medications in each
group, see Appendix C. The unexposed group was comprised of women who were not prescribed
any BD psychotropic treatment during pregnancy.
Exposed women were further categorized into medication class groups (all combinations of
mood stabilizers, antipsychotics, antidepressants, and anxiolytics). Women in any of the
psychotropic treatment categories required two consecutive filled prescriptions of any one of the
therapeutic classes, mood stabilizers, antidepressants, antipsychotics, or anxiolytics. The
different classes of medication were created by individually selecting relevant drugs from the
ODB formulary and grouping them into their respective classes. Two consecutive prescriptions
were required to increase the likelihood that the woman was taking the medication for the
prescribed duration. Prescriptions were considered consecutive if it was filled within 1.5 times
the number of supply days, prior to or after the prescription. For example, if the first prescription
during pregnancy was a 30-day supply, there should be another prescription filled within 1.5x30
days (45 days) before or after the date of the first prescription for it to be deemed consecutive.
This extra window of time captures those women who may fill their prescription after their last
day of supply. If patients did not refill a second prescription within the allowed time span after
their first prescription, then they were considered to have a treatment interruption. Women who
only had one prescription filled were excluded so they were not classified as unexposed. All
others who did not fall into the above criteria were classified into the non-exposed comparison
group.
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Figure 3.1 Outline of patient time-frame of exposure and outcome

3.4.2 Outcome Variables
Outcome variables were selected because they are considered to be clinically important
indicators of maternal and neonatal health and they have been previously studied with regards to
psychotropic drug use and adverse outcomes in pregnancy.122
Gestational diabetes: This is a type of diabetes mellitus defined as any degree of glucose
intolerance, with the onset or first recognition during pregnancy. Diagnosed cases of gestational
diabetes were identified from an outpatient (OHIP) or inpatient (CIHI-DAD) claim. A study
examined the validity of ICD-10 codes for gestational diabetes in administrative databases
relative to glucose thresholds from laboratory data and found a high estimated sensitivity (92%)
and specificity (97%) when combining outpatient and inpatient datasets.171
Gestational hypertension: This condition is characterized by high blood pressure without the
presence of excess protein in the urine. High blood pressure is defined by a systolic blood
pressure of at least 140 mm Hg and/or a diastolic blood pressure of at least 90 mmHg, present on
two separate occasions, at minimum six hours apart. Gestational hypertension was identified
using CIHI-DAD discharge diagnosis codes, which is a validated method with a sensitivity of
83%.173
Venous thromboembolism (VTE): This is a potentially lethal disorder that encompasses two
conditions, deep vein thrombosis and pulmonary embolism. The condition occurs when blood
clots form, commonly in the deep veins of a leg (deep vein thrombosis) and can travel to the
lungs (pulmonary embolism). Inpatient and outpatient diagnostic claims were used to ascertain
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VTE. Using inpatient claims has been deemed reasonably accurate, as one study has reported an
estimated sensitivity of 87% and 78% for deep vein thrombosis and pulmonary embolism,
respectively.174
Pre-eclampsia or eclampsia: Pre-eclampsia is a disorder that is similar to gestational
hypertension, in which it is diagnosed as a result of high blood pressure in patients who may not
have experienced high blood pressure before. It is marked by significant amounts of protein in
urine, which is a clinical indicator for abnormal kidney function. Pre-eclampsia can progress into
eclampsia, which is commonly characterized by the development of seizures. Preeclampsia and
eclampsia were identified using diagnostic codes, a method that has previously been validated. A
Canadian study reported a sensitivity of 75% and a specificity of 99% using codes from CIHIDAD. 173
Placental Abruption: This is a condition where the placenta prematurely separates from the
uterine lining and can lead to complications such as bleeding, or in severe cases, fetal death.
Inpatient and outpatient diagnostic codes were used to identify cases of placental abruption. To
our knowledge, this method has not been validated.
Placental Infarction: This condition arises when there is an interruption in the blood flow to a
part of the placental, leading to cell death. Severe cases may lead to placental insufficiency,
potentially resulting in fetal death. Inpatient diagnosis codes were used to identify cases of
placental infarction, though to our knowledge, this method has not been validated.
Maternal Mortality: This term describes the death of a woman from any cause, during pregnancy
or within 42 of the delivery. Data on maternal mortality were obtained from the RPDB.
Transfer to Intensive Care Unit (ICU): Women who were transferred to the medical, surgical, or
trauma ICU during pregnancy were flagged. Given that most women progress through pregnancy
without any major adverse events, a transfer to ICU can be an indicator of a pregnancy or
delivery with major complications. A CIHI-DAD variable was used to identify transfers, which
has not yet been validated.
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Stillbirth: Fetal death that occurs at or after 20 weeks of gestation is referred to as stillbirth.
There is no one cause of stillbirth, which is a result of a number of possible causes that may lead
to fetal death. These causes can be direct, such as a genetic defect, or it may be an indirect cause
from a complex chain of events that precede the fetal death. Stillbirth events were identified
using a variable from MOMBABY.
Congenital Malformations: These are occurrences of structural or functional anomalies that take
place in intrauterine life and can be identified prenatally. Outpatient and inpatient diagnostic
codes were used to identify cases of malformations, which has not been previously validated.
Preterm birth: This is defined as the birth of a baby at or before 37 weeks of gestational age.
Problems arise as a result of immature organ systems that are not yet fully developed to support
life. This variable was derived using baby weight variable in DAD.
Small for gestational age (SGA): This term refers to fetal growth restriction where a newborn’s
birth weight is lower than the normal threshold for a given gestational age and sex. Using the
population-based Canadian reference tables, we classified all babies born with a birth weight
below the 10th percentile for their gestational age and sex as SGA. This variable was derived
using maternal gestational week and baby weight variable in DAD.
Large for gestational age (LGA): This term refers to babies with birth weights that are above the
normal threshold for a given gestational age and sex. Similar to SGA, using the population-based
Canadian reference tables, we classified all babies born with a birth weight above the 90th
percentile for their gestational age and sex as LGA. This variable was derived using maternal
gestational week and baby weight variable in DAD.
Neonatal Sepsis: Sepsis refers to the human body’s immune response to attack its organs and
tissues as a result of presence of harmful bacteria/virus or toxin in the bloodstream. If not
recognized early and treated in time, sepsis can progress into septic shock and death. For the
purpose of this study, sepsis was an outcome if observed within 90 days of delivery. Events were
identified using neonatal and adult codes from CIHI-DAD. A validation study found moderate
level of accuracy, with a sensitivity of 67%.173
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Neonatal mortality: This refers to a child’s death occurring within the first 27 days of life. This
data was obtained from the RPDB.
Neonatal Infection: This was defined as a diagnosis of an infection, from any cause, within 4
weeks of delivery. Infections are a result of bacteria, viruses, and fungi, which can be lifethreatening given the infant’s underdeveloped immune system and without adequate control,
may lead to sepsis and death. We used outpatient CIHI-DAD and inpatient OHIP codes to
identify the occurrence of infection. Accuracy using this method has not been validated
previously.
Neonatal Adaptation Syndrome: This term refers to a set of neurobehavioural symptoms in
infants born to mothers taking certain drugs during pregnancy, which can include antidepressants
and benzodiazepines. These symptoms are thought to be a result of withdrawal from fetal
exposure to the drug after delivery. Symptoms that neonates may manifest include jitteriness,
feeding problems, respiratory distress, and hypoglycemia.175 The window of time for diagnosis
of neonatal adaptation syndrome for this study was one-year post delivery. These diagnostic
codes have not been validated previously.
Respiratory Distress Syndrome (RDS): This event is diagnosed when a neonate’s lungs are not
sufficiently developed. Specifically, this occurs when there is not enough surfactant produced by
the lungs, a liquid that allows the lung’s airways to remain open for oxygen inhalation. Lack of
surfactant affects lung function and reduces the amount of oxygen inhaled, consequently
increasing carbon dioxide buildup in the blood, leading to progressive organ dysfunction. RDS
was captured if diagnosis occurred within one year of delivery. Outpatient diagnostic codes from
CIHI-DAD were used. A validation study has reported a low accuracy (estimated sensitivity of
50%) from using codes, however, the sensitivity increases in comparison if restricted to severe
cases of RDS (96%).173
Neonatal Seizures: Seizures are classified as sudden, incontrollable neuronal activity in the brain.
Those that occur during the neonatal period are often indicators of serious damage to the brain.
Seizure was captured as an outcome in the study if it was diagnosed within one year of delivery.
Inpatient OHIP and outpatient CIHI-DAD codes were used to identify seizures, which to our
knowledge, has not been previously validated.
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Neonatal Intraventricular haemorrhage (IVH): This term refers to bleeding inside or around the
ventricles of the brain, the place where the cerebral spinal fluid is produced. A buildup of
pressure from the bleeding can damage nerve cells, leading to brain injury. IVH was included as
an outcome event if it occurred anytime within one year of delivery. Outpatient CIHI-DAD
codes were used to ascertain IVH, this has not been previously validated for accuracy.
Cesarean Delivery: This describes a planned or unplanned surgical procedure where a baby is
delivered through a through an incision in the abdomen and uterus. Since it is a major surgery, it
carries a higher risk than a vaginal delivery. In most cases, this delivery is performed when a
vaginal delivery is high risk for the mother or baby.176 We used CIHI-DAD procedural codes to
identify caesarean delivery, which has shown to be coded accurately (estimated sensitivity of
99.8%; estimated specificity of 98.7%).169,173
Forceps or Ventouse Delivery: Forceps and ventouse are two types of tools that are used to assist
in delivery of a baby. Forceps is a tong-type surgical instrument and ventouse is a vacuum device
with gentle suction, both help guide the fetus out the birth canal during delivery. Assisted
delivery is considered when there is a need for immediate delivery, the fetus does not move
towards the birth canal for delivery, or the mother is not physically able to progress through the
delivery. We used CIHI-DAD procedure codes to identify assisted delivery, which have been
validated for accuracy (estimated sensitivity of 99.8%).169
Induced Labour: This is the process by which labour is artificially induced with the use of
pharmacological medications or mechanical means. This takes place when it is considered
clinically safer for a fetus to be delivered than continue through pregnancy. Induction was
classified using CIHI-DAD procedural codes, which is found to be completely accurate in
identification (estimated sensitivity of 100%).169
Episiotomy or delivery with tear (3rd or 4th degree): An episiotomy is a surgical incision to
create an opening in the perineum, the area between the vagina and anus, to widen the opening
and deliver the baby. If no incision is made, a tear can unexpectedly occur during delivery.
Tears are described in degrees, depending on their size and the affected area. Third and fourth
degrees are severe tears where lacerations extend to the anal sphincter. We used CIHI-DAD
diagnostic codes for both outcomes. Though diagnostic codes for episiotomy have not been
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validated, codes for perineal tear have been shown to be very accurate, with an estimated
sensitivity of 97% and 94% for 3rd and 4th degree tears respectively.173
Readmission for Mental Health: Readmission represents the proportion of occurrences of an
unplanned admission to a hospital for any psychiatric cause within a specific time. Given that
readmission is most often sought when outpatient or community-based care is not sufficient, it
can reflect poor transition care or coordination to community care, severity of illness, and
appropriateness of medication upon discharge. In the current study, it could also be indicative of
a postpartum recurrence of a mood episode. This study used two time points for psychiatric
readmission: within 7 days and within 12 weeks.

3.4.3 Potential Confounding Factors
The potential confounding factors included in all analyses were based on evidence from the
literature that they are associated with the outcomes of interest, as well as availability of the
variable in the ICES databases (Appendix E). Covariates included maternal age, number of
previous births, neighbourhood-level income, obesity, prior alcohol-related or substance-related
disorders, history of suicide attempt, number of prior BD hospitalizations, number of prior
emergency department visits, and recurrence episode in current pregnancy. Maternal age was
categorized into four groups (13-19, 20-29, 30-39, 40-50), number of previous births into three
categories (0, 1, 2+), and income into quintile-based categories. All other characteristics were
binary.

3.5 Outcomes
We grouped all outcome indicators into six composite groups: maternal outcomes in pregnancy,
maternal outcomes postpartum, neonatal outcomes, fetal outcomes, labour and delivery
outcomes, and psychiatric readmission outcomes. Composite groups are those in which several
individual outcomes are pooled to produce a single outcome. Because many of the outcome
measures are rare, this was done to increase the number of events for statistical analysis. Each
indicator within each composite outcome was selected to be included if it was: (1) classified as a
clinically important health indicator and a major determinant of perinatal morbidity and
mortality; (2) accurately measured; and (3) available in the ICES data holdings. Composite
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groups were created based on the person (fetus/newborn or mother) and the timing of the
outcome (pregnancy, delivery, postpartum). The use of composite outcomes is in line with
typical prenatal care, which often aims to prevent multiple complications at a time as opposed to
a singular outcome.177 Table 3.1 lists all the outcomes for each composite group. Composite
groups were created as binary variables, where if any one of the included outcomes takes place,
it grants the composite group a positive event.
Table 3.1 List of outcomes included within each composite group
Composite Groups

Outcome Indicators

Neonatal Outcomes

Preterm birth, small for gestational age, large for
gestational age, sepsis, mortality, infection, neonatal
adaption syndrome, respiratory distress syndrome,
seizure, intraventricular haemorrhage
Stillbirth, congenital malformation

Fetal Outcomes
Maternal Outcomes (pregnancy)

Maternal Outcomes (post-pregnancy)
Labour and Delivery Outcomes
Psychiatric Readmission

Venous Thromboembolism, gestational diabetes,
gestational hypertension, preeclampsia or eclampsia,
placental abruption, placental infarction
Transfer to ICU, maternal mortality
Caesarean, forceps/ventouse, induced labour,
episiotomy or delivery with tear (3rd or 4th degree)
Readmission for mental health reasons ≤ 7 days postdelivery, readmission for mental health reasons within 1
to 12 weeks post-delivery

3.6 Statistical Analyses
Stata (Version 13) was used for all analyses in this study.178 For women with multiple
pregnancies over the study period, only the first pregnancy was retained for analysis. Univariate
analyses were conducted to describe the sample in terms of sociodemographic characteristics,
pre-morbid conditions, current pregnancy and delivery factors, and health service use. Median
and interquartile range (IQR) was reported for continuous variables and frequencies and
proportions for categorical variables.
Our first objective was to describe the BD prescription patterns during pregnancy. We derived all
combinations of treatment use in pregnancy between the four therapeutic classes. A graph was
derived with frequencies for each drug class used during pregnancy across the study period.
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Our second objective was to identify patient-level factors associated with use of treatment
regimens for BD in pregnancy. Treatment groups were compared to no treatment in pregnancy.
We ran unadjusted and adjusted modified Poisson regression models with robust variance
estimation the log link function to avoid overestimation of the standard error.179 This provides a
direct estimation of prevalence ratios (PR) for each exposure, comparing the treatment group of
interest with the no treatment unexposed group. This was repeated for each treatment group.
Results are presented as PR with 95% confidence intervals (CI). Typically log-binomial
regression model is the preferred method to approximate prevalence ratios,180 however, the
model failed to converge, which is a common occurrence in the presence of continuous
independent variables in the model.181 Poisson regression model with robust variance estimates
is an alternative option to yield estimates of the prevalence ratio.182
Our third and fourth objectives were to assess the impact of treatment use on various pregnancy
outcomes, delivery outcomes, and mental health service use. We ran unadjusted and adjusted
Poisson regression models with robust error variance, which produced estimates of risk ratio
(RR).179 The complete list of covariates associated with each outcome and the descriptions of
their associations is summarized in Appendix F. Each treatment group was compared with the no
medication group to evaluate the association with each composite outcome. Results are presented
as risk ratios with 95% CIs.
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Chapter 4

4

Results

This chapter summarizes the study findings, beginning with the descriptive statistics and the
overall trend of psychotropic medication use during the period of pregnancy between 2002 and
2014 among women with BD. This is followed by a summary of the relationship between patient
characteristics and BD medication use, and an analysis of the impact of BD treatment during
pregnancy on perinatal outcomes.

4.1 Description of Study Cohort
A total of 5005 pregnancies met the eligibility criteria for the current study. Of these, repeat
pregnancies were removed, as well as observations with missing data in any variables of interest
(<10%).The final dataset for analysis included 3357 unique women. A detailed breakdown of the
cohort derivation is shown in the study flow chart (Figure 4.1).
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Figure 4.1 Cohort selection study flowchart

All birth records from ICES
database between 2002 and
2014 (n=1,825,703)

5005 Observations

Exclusions:
 Not singleton delivery (n=140,204)
 Non-Ontario residents (n=2416)
 Ages <13 or >50 (n=566)
 Not female according to RPDB (n=59)
 Gestational weeks <20 or >45 (n=3603)
 Data inconsistencies (n=11)
 Duplicate pregnancy records (n=232)
 Women sharing baby IKN numbers (n=546)
 Unable to classify conception date (n=108)
 Did not have BD before conception
(n=1,666,602)
 No prescription in ODB in 6 months prior to
pregnancy to 6 months after delivery
(n=6351)

Remove duplicate of study ID (multiple
pregnancies) keeping only first occurrence (n=1343)

3662 Observations
Total observations with missing data (<10%)
(n=305):
Income (n=9)
Previous Birth (n=9)
Sex of Baby (n=206)
Previous Preterm Birth (n=60)
Gestational Weeks (n=60)
Baby Weight (n=149)
3357 Birth Records
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4.2 Patterns of BD Treatment in Pregnancy
Among all women diagnosed with BD in Ontario with a conception date between 2002 and
2014, 25% (n=852) were prescribed psychotropic medication during the period of pregnancy. All
combinations of the four psychotropic medication classes (mood stabilizers, antidepressants,
antipsychotics, and anxiolytics) were derived. The frequency of each possible drug combination
between the four drug classes is presented in Figure 4.2. Among all patients with BD using
psychotropic medication during pregnancy, 74% (n=633) were prescribed medications from a
single therapeutic drug class (monotherapy; therapeutic drug classes include mood stabilizers,
antipsychotics, antidepressants, or anxiolytics), whereas 26% (n=219) were on polytherapy,
where patients are prescribed two or more classes of psychotropic drugs across the therapeutic
drug classes. Monotherapies ranked from most to least prescribed during pregnancy in BD
patients were as follows: antipsychotics, antidepressants, mood stabilizers, and anxiolytics.
Overall, the three most commonly prescribed medication regimens were antipsychotic
monotherapy, antidepressant monotherapy, and antipsychotic-antidepressant polytherapy. Given
the low frequency of other treatment combinations, we made a post-hoc decision to examine
only the three most common medication combinations for the remaining analyses. These three
groups also allowed us to examine the effect of antipsychotic and antidepressant monotherapy, as
well as the combined effects of using at least one agent from the two drug classes at once.
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DRUG CLASS COMBINATIONS

Figure 4.2 Frequency graph of all drug combinations prescribed to women in pregnancy
for bipolar disorder between 2002 and 2014 in Ontario
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Abbreviations: AP, Antipsychotics; AD, Antidepressants; MS, Mood Stabilizers; AA, Anxiolytics

4.3 Sample Characteristics
The sample characteristics by treatment group are presented in Table 4.1. Across the treatment
groups, the largest proportion of the study sample belonged to the 20-29 year age bracket,
whereas the group with the lowest proportion was the 40-50 year group. With regards to previous
births, most of the sample had no previous births and resided in the lowest neighbourhood
income level (quintile category 1). The frequencies of obesity-related disorders (17%),
recurrence episodes in pregnancy (30%), and diagnosis of placental previa (4.5%) among
antipsychotic users were higher than in the other treatment groups. More than half of the
antidepressant monotherapy sample (56%) were previously diagnosed with substance-related
disorders, whereas a larger proportion of those on a polytherapy regimen were previously
diagnosed with alcohol related disorders (32%), gestational diabetes (6%), preeclampsia or
eclampsia (3%), or had higher rates of previous psychiatric emergency department visits (30%).
The proportions were nearly identical between the treatment groups for previous diagnosis of
attempted suicide, hypertension, diabetes, thromboembolic disease, preterm birth, current
epidural use, and prior psychiatric admission rates.
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Table 4.1 Baseline characteristics of treatment exposed and non-exposed women in
pregnancy
No Drug Use
in Pregnancy
(n=2505)

Demographic
Age Group n (%) (years)
13-19
20-29
30-39
40-50
Number of Previous Births
0
1
2+
Income category
1- Lowest neighbourhood income
category
2
3
4
5
Comorbid Disorders
Obesity Related Disorders
Alcohol Related Disorders
Substance Related Disorders
Attempted Suicide
History of Gestational Diabetes
Pre-existing Hypertension
Pre-existing Diabetes
Previous Pregnancy with
Preeclampsia/Eclampsia
Previous Pregnancy with
Thromboembolic Disease
Previous Preterm Birth
Current Pregnancy or Delivery
Recurrence of Mood Episode
Rapid Repeat Pregnancy
Placental Previa
Use of Epidural
Health Service Use
Number of BD Hospitalizations Prior
to Pregnancy, median (IQR)
Psychiatric Emergency Department
Visits Prior to Pregnancy

Antipsychotic
Treatment in
pregnancy
(n=375)

Antidepressant
Treatment in
Pregnancy
(n=149)

Antipsychotic
and
Antidepressant
Polytherapy
(n=63)

187 (7.5)
1427 (57.0)
815 (32.5)
(<5%)a

28 (7.5)
222 (59.2)
117 (31.2)
(<5%)a

(<5%)a
80 (53.7)
59 (39.6)
(<5%)a

(<5%)a
32 (50.8)
29 (46.0)
(<5%)a

1140 (45.5)
702 (28.0)
663 (26.5)

185 (49.3)
104 (27.7)
86 (22.9)

66 (44.3)
42 (28.2)
41 (27.5)

31 (49.2)
16 (25.4)
16 (25.4)

1069 (42.7)

183 (48.8)

59 (39.6)

27 (42.9)

593 (23.7)
382 (15.3)
266 (10.6)
(<5%)a

86 (22.9)
43 (11.5)
38 (10.1)
25 (6.7)

33 (22.2)
27 (18.1)
18 (12.1)
12 (8.1)

11 (17.5)
7 (11.1)
12 (19.1)
6 (9.5)

339 (13.5)
580 (23.2)
1126 (45.0)
237 (9.5)
(<5%)a
(<5%)a
(<5%)a
(<5%)a

62 (16.5)
76 (20.3)
179 (47.7)
43 (11.5)
(<5%)a
(<5%)a
(<5%)a
(<5%)a

17 (11.4)
37 (24.8)
83 (55.7)
15 (10.1)
(<5%)a
(<5%)a
(<5%)a
(<5%)a

7 (11.1)
20 (31.8)
32 (50.8)
7 (11.1)
4 (6.4)
(<5%)a
(<5%)a
(<5%)a

(<5%)a

(<5%)a

(<5%)a

(<5%)a

297 (11.9)

47 (12.5)

20 (13.4)

9 (14.3)

495 (19.8)
(<5%)a
(<5%)a
(<5%)a

113 (30.1)
(<5%)a
(<5%)a
(<5%)a

29 (19.5)
(<5%)a
(<5%)a
(<5%)a

17 (27.0)
(<5%)a
(<5%)a
(<5%)a

(<5%)a

(<5%)a

(<5%)a

(<5%)a

594 (23.7)

106 (28.3)

29 (19.5)

19 (30.2)

a- ICES does not allow reporting of cell values of less than 6
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4.4 Composite Outcomes
Composite outcomes were created using various outcome indicators, and the frequency of each is
reported in Table 4.2. The most frequent composite outcome among all pregnant women with
BD was labour and delivery outcomes (56%), followed by neonatal outcomes (42%), maternal
outcomes in pregnancy (9.0%), fetal outcomes (8.5%), psychiatric readmission outcomes (3.3%),
and maternal outcomes post-pregnancy (0.4%). The number of observations in the composite
group maternal outcomes post-pregnancy group was very low (<2%) and was therefore was
dropped from the analyses.
Table 4.2 Frequency of events of composite outcomes by treatment combinations

No Drug
(n=2505)

Maternal Outcomes
Pregnancy (n=303)
Maternal Outcomes
Post-Pregnancy (n=15)
Fetal Outcomes (n=287)
Neonatal Outcomes
(n=1394)
Labour and Delivery
Outcomes (n=1867)
Psychiatric Readmission
(n=109)

Bipolar Disorder Treatment Classes
Antipsychotic Antidepressant Antipsychotic
(n=375)
(n=149)
and
Antidepressant
(n=63)

238 (9.5%)

40 (10.67%)

13 (8.72%)

12 (19.05%)

(<5%)a

(<5%)a

(<5%)a

(<5%)a

224 (8.94%)
1119 (44.67%)

38 (10.13%)
174 (46.40%)

18 (12.08%)
68 (45.64%)

7 (11.11%)
33 (52.38%)

1501 (59.92%)

231 (61.60%)

93 (62.42%)

42 (66.67%)

(<5%)a

(<5%)a

(<5%)a

(<10%)a

a- ICES does not allow reporting of cell values of less than 6

4.5 Factors Associated with Type of Medication Use
Our second objective was to determine whether patient characteristics were associated with the
use of antipsychotic, antidepressant, or antipsychotic and antidepressant polytherapy during
pregnancy, compared to no medication use. Unadjusted and adjusted prevalence ratio estimates
from the analysis are presented in Table 4.3-4.5. In the adjusted models, we found an association
between history of suicide attempts and antipsychotic prescription, whereby patients with suicide
attempts were 1.45 times (95% CI=1.03-2.04) more likely to be prescribed antipsychotics than
those using no psychotropic medication during pregnancy. Additionally, patients who
experienced a recurrence during their pregnancies were 1.58 times (95% CI=1.20-2.10) more
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likely to be prescribed antipsychotic monotherapy while those with a prior alcohol related
disorder had a lower prevalence of antipsychotic monotherapy (PR=0.69, 95% CI=0.50-0.94)
than those who use no medication during pregnancy. Women with a history of obesity-related
disorders had a lower prevalence of antidepressant monotherapy (PR=0.36, 95% CI=0.15-0.87)
compared to those using no psychotropic medication in pregnancy. Lastly, with every one-unit
increase in the number of psychiatric emergency department visits prior to pregnancy, women
were 1.08 times (95% CI=1.03-1.13) more likely to be prescribed antipsychotic and
antidepressant polytherapy.
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Table 4.3 Association between patient characteristics and prescriptions for antipsychotic
monotherapy in pregnant women with bipolar disorder
Antipsychotics (n=375)
Unadjusted PR (95%
CI)

Adjusted PR (95%
CI)

Age Group
13-19

0.97 (0.67-1.40)

0.95 (0.61-1.49)

20-29

Reference

Reference

30-39

0.93 (0.76-1.15)

1.00 (0.76-1.32)

40-50

0.71 (0.36-1.38)

0.42 (0.14-1.30)

0

Reference

Reference

1

0.92 (0.74-1.16)

0.97 (0.73-1.30)

2+

0.82 (0.65-1.05)

0.86 (0.62-1.20)

1- Lowest neighbourhood income category

Reference

Reference

2

0.87 (0.68-1.10)

0.85 (0.63-1.15)

3

0.69 (0.51-0.95)*

0.61 (0.40-0.94)*

4

0.86 (0.62-1.19)

0.90 (0.61-1.33)

5

0.78 (0.52-1.15)

0.75 (0.45-1.25)

Prior Obesity Related Disorders

1.22 (0.95-1.57)

1.22 (0.88-1.69)

Prior Alcohol Related Disorders

0.86 (0.68-1.09)

0.69 (0.50-0.94)*

Prior Substance Related Disorders

1.10 (0.91-1.33)

1.19 (0.92-1.55)

History of Suicide Attempt

1.20 (0.90-1.61)

1.45 (1.03-2.04)*

Recurrence of Mood Episode in Current Pregnancy

1.61 (1.32-1.97)*

1.58 (1.20-2.10)*

Number of BD Hospitalizations Prior to Pregnancy

1.03 (0.99-1.08)

1.00 (0.95-1.06)

Number of Psychiatric Emergency Department Visits
Prior to Pregnancy

1.03 (1.00-1.06)*

1.02 (0.98-1.05)

Number of Previous Births

Income

* p< 0.05
CI=confidence interval
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Table 4.4 Association between patient characteristics and prescriptions for antidepressant
monotherapy in pregnant women with bipolar disorder
Antidepressants (n=149)
Unadjusted PR (95%
CI)

Adjusted PR (95%
CI)

Age Group
13-19

0.59 (0.26-1.32)

0.64 (0.26-1.56)

20-29

Reference

Reference

30-39

1.27 (0.92-1.76)

1.17 (0.75-1.82)

40-50

0.94 (0.35-2.51)

0.86 (0.27-2.70)

0

Reference

Reference

1

1.03 (0.71-1.50)

0.70 (0.42-1.16)

2+

1.06 (0.73-1.55)

0.88 (0.52-1.48)

1- Lowest neighbourhood income category

Reference

Reference

2

1.01 (0.67-1.52)

1.25 (0.75-2.07)

3

1.26 (0.81-1.96)

1.90 (1.13-3.19)*

4

1.21 (0.73-2.02)

0.99 (0.48-2.04)

5

1.01 (0.61-2.03)

1.27 (0.61-2.68)

Prior Obesity Related Disorders

0.83 (0.51-1.36)

0.36 (0.15-0.87)*

Prior Alcohol Related Disorders

1.09 (0.76-1.56)

0.97 (0.61-1.55)

Prior Substance Related Disorders

1.50 (1.10-2.06)*

1.21 (0.81-1.83)

History of Suicide Attempt

1.07 (0.64-1.79)

1.05 (0.54-2.02)

Recurrence of Mood Episode in Current Pregnancy

0.98 (0.66-1.46)

1.34 (0.82-2.20)

Number of BD Hospitalizations Prior to Pregnancy

1.04 (0.96-1.13)

1.03 (0.94-1.13)

Number of Psychiatric Emergency Department Visits
Prior to Pregnancy

0.96 (0.87-1.06)

0.97 (0.86-1.08)

Number of Previous Births

Income

* p< 0.05
CI=confidence interval
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Table 4. 5 Association between patient characteristics and prescriptions for antipsychotic
and antidepressant polytherapy in pregnant women with bipolar disorder
Antipsychotic and Antidepressant
Polytherapy (n=63)
Unadjusted PR (95%
Adjusted PR (95%
CI)
CI)
Age Groups
13-19

0.24 (0.03-1.77)

0.34 (0.05-2.47)

20-29

Reference

Reference

30-39

1.57 (0.95-2.57)

1.65 (0.88-3.10)

40-50

0.59 (0.08-4.27)

0.89 (0.12-6.42)

0

Reference

Reference

1

0.84 (0.46-1.53)

0.87 (0.42-1.80)

2+

0.89 (0.49-1.62)

0.81 (0.38-1.73)

1- Lowest neighbourhood income quintile

Reference

Reference

2

0.74 (0.37-1.48)

1.13 (0.49-2.57)

3

0.73 (0.32-1.66)

1.26 (0.48-3.29)

4

1.75 (0.90-3.41)

2.58 (1.14-5.85)*

5

1.21 (0.51-2.90)

1.96 (0.72-5.33)

Prior Obesity Related Disorders

0.80 (0.37-1.75)

0.97 (0.41-2.31)

Prior Alcohol Related Disorders

1.53 (0.90-2.57)

0.96 (0.47-1.98)

Prior Substance Related Disorders

1.26 (0.77-2.05)

1.20 (0.64-2.26)

History of Suicide Attempt

1.19 (0.55-2.58)

1.09 (0.41-2.85)

Recurrence of Mood Episode in Current Pregnancy

1.48 (0.86-2.57)

0.91 (0.41-2.01)

Number of BD Hospitalizations Prior to Pregnancy

1.05 (0.98-1.12)

1.01 (0.94-1.09)

Number of Psychiatric Emergency Department Visits
Prior to Pregnancy

1.07 (1.03-1.11)*

1.08 (1.03-1.13)*

Number of Previous Births:

Income (quintile)

* p< 0.05
CI=confidence interval

4.6 Treatment Use and Study Outcomes
The third and fourth objectives involved examining the association between antipsychotic
monotherapy, antidepressant monotherapy, or antipsychotic and antidepressant polytherapy and
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pregnancy and psychiatric outcomes (Table 4.6). The results of the multivariable regression
models suggest that women on antipsychotic and antidepressant polytherapy were almost twice
as likely (RR=1.73, 95% CI 0.99-3.01) to experience adverse maternal outcomes in pregnancy
compared to women prescribed no psychotropic medication. There was no statistically
significant association between the type of treatment and neonatal, fetal, labour and delivery, and
psychiatric outcomes. A table with all unadjusted and adjusted estimates of the effect of
treatment group, and the covariates for each composite outcome model, is included in
Appendices G through K.
Table 4.6 Association between use of treatment combinations in pregnancy and all study
outcomes

Maternal
RR (95% CI)

Neonatal
RR (95% CI)

Antipsychotic
Treatment
Antidepressant
Treatment

1.04
(0.80-1.35)
0.94
(0.60-1.49)

1.03
(0.92-1.16)
1.00
(0.84-1.20)

Antipsychotic and
Antidepressant
Polytherapy

1.73
(0.99-3.01)

1.13
(0.90-1.43)

Study Outcomes
Fetal
Labour and
RR (95% CI)
Delivery
RR (95% CI)
1.11
1.02
(0.80-1.54)
(0.93-1.11)
1.33
1.03
(0.85-2.09)
(0.91-1.17)
1.16
(0.57-2.37)

1.08
(0.91-1.30)

Psychiatric
Readmission
RR (95% CI)
0.79
(0.40-1.58)
1.22
(0.53-2.85)
1.24
(0.39-4.00)

CI=confidence interval
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Chapter 5

5

Discussion

This chapter discusses the primary findings of this study and the clinical implications.
Additionally, it presents a detailed account of the strengths and limitations of the study.

5.1 Introduction
Although avoiding psychotropic medication in pregnancy may be desirable, it is often not safe to
do so due to the severity of an underlying mental illness. BD is a mental disorder that often
requires ongoing treatment, including during pregnancy. Thus, it is extremely important to
evaluate the safety of commonly used treatments for BD in pregnancy. The primary objective of
this thesis was to examine the risk of adverse outcomes among women using different
medication combinations during pregnancy. Specifically, we addressed the potential risks
associated with the use of antipsychotics, antidepressants, mood stabilizers, and antianxiety
drugs, which we found to be the most commonly used types of medication in this population.
The outcomes we assessed included maternal, fetal, neonatal, labour and delivery, and
psychiatric readmissions. Additionally, we described the patterns of medication use in pregnant
women diagnosed with BD, and explored characteristics of the women with BD who use
medication in pregnancy.

5.2 Interpretation of Study Results
5.2.1 Psychotropic Treatment Patterns
We obtained a dataset containing data on ODB-eligible women diagnosed with BD with a record
of a singleton delivery and a conception date between 2002 and 2014. In the study sample, 25%
were prescribed at least one psychotropic medication during pregnancy and of those, 74% were
on a monotherapy regimen whereas 26% were using two or more psychotropic medications. This
proportion was considerably lower than what has been previously reported – Broeks et al. found
that 53% of their sample redeemed at least one prescription during pregnancy, the percentage
increased to 58% after considering women who had dispensed prior to pregnancy and had a
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supply that lasted past conception date.158 This was a less conservative exposure definition than
was used in the current study.
Two studies by Broeks et al. and Boden et al., reported prevalence estimates of mood stabilizer
treatment use in pregnancy of 37% and 6%, respectively. The discrepancy between the two
studies is likely due to the difference in the definition used to define mood stabilizers. Boden et
al., included antipsychotic medications in their definition, while Broeks et al. did not. In this
study, prevalence of mood stabilizer was estimated at 1.6%, which is comparatively lower than
what was reported previously. It is important to note that the study by Broeks et al. was based out
of Denmark where they collect population level data on prescriptions which can be accessed
from a national drug registry. Among all treated patients, Broeks et al. reported 11% of their
sample using mood stabilizer monotherapy. In this study, approximately 6% of all treated
mothers were using mood stabilizers. The low rate in this study may be explained by the general
knowledge of adverse teratogenic outcomes associated with some mood stabilizers – namely,
anticonvulsants, such as valproate and carbamazepine. However, this is unlikely to fully explain
the low rate of use of mood stabilizers, as the mainstay treatment for BD is lithium, which is
recommended as one of the first-line treatment for mood stabilizing in pregnancy.96,183–185
Studies on psychotropic drug utilization in the larger population of patients with BD have
reported a decreasing trend in mood stabilizer prescriptions over time.11,186–188 The reason behind
this declining use has been lithium’s reputation as being a burden to use, coupled with the
increase in the availability of other treatment options.189 Patients on lithium often need
monitoring of serum lithium levels on a regular basis to optimize treatment effectiveness and
prevent toxicity, and adequate dosing is especially important for the period of pregnancy.190
Additionally, lithium is not without side-effects, which is concerning for clinicians and patients.
Because there are no recommendations for lithium in pregnancy in current guidelines, it is likely
that clinicians are cautious when prescribing, possibly discontinuing completely during
pregnancy, which reflect the trends observed in this study.
Antipsychotics were the most frequently prescribed type of medication in pregnancy in this study
sample, followed by antidepressants. This is in agreement with Canadian guidelines, as
antipsychotics are among the first-line options for treatment (along with mood stabilizers). The
high rate of antipsychotic prescriptions reflect an increasing trend observed in the broader
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population of women with BD. For example, Hayes et al. examined prescribing practices for
patients with BD from 1995 to 2009 and found that the frequency of prescription of
antipsychotics increased dramatically.191 Similar changes have been described in Denmark as
well. A large, nationwide population-based study examined medications prescribed over the
period 2000–2011. The authors found that prescribing of antipsychotics increased significantly
over the study period, and that they were the first option of drugs prescribed by 2011.11
Antipsychotics are an alternative to mood stabilizers for BD patients who are not responsive to
the latter,192 and their more favorable side-effect profile also may warrant their use in lieu of
other drug classes.193 They have also been shown to be the preferred treatment for patients who
present with manic and mixed episodes or with more severe episodes.194
We found that 17% of the women taking psychotropic medications were using antidepressant
monotherapy, also widely prescribed in the broader BD population.195,196 Broeks et al. reported a
prevalence of 41% using antidepressant monotherapy in a population of pregnant BD women.158
This high prevalence is a worrisome given that the use of antidepressants without concomitant
use of another drug is not recommended in practice.3 Antidepressant use in absence of a
concurrent mood stabilizer has been shown to increase risk of treatment-emergent affective
switches to mania.84 This is especially problematic if induced during the period of pregnancy, as
a BD episode can potentially compromise the health of the mother or the fetus. Switching may
not occur when antidepressants are used in conjunction with a mood stabilizer or an
antipsychotic agent,96 which explains the antipsychotic and antidepressant polytherapy group
being the third most prescribed combination of treatment in pregnant BD women in this study.
The proportion of women using medications from more than one drug class was 26%. This did
not come as a surprise given that polytherapy has become a common treatment regimen for BD
patients.11,191 Studies have also shown higher efficacy of some combination therapy compared to
monotherapy for BD treatment.96 Broeks et al. reported a much higher prevalence of polytherapy
in their sample of pregnant women. They examined the proportion of people using more than one
class of treatment for at least 90 days and found that 38% of their sample were using
combination therapy (as per their definition), and an additional 19% were also using combination
therapy but for less than 90 days. Taken together, approximately 57% of the sample were on
combination therapy during pregnancy. Though the proportion found in this study was
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considerably lower, we cannot make a direct comparison because their study specifically used a
90-day overlap as the criterion for polytherapy. A lower proportion reported in this study may be
a result of the absence of available sources of population-wide prescription data used to ascertain
treated cases.

5.2.2 Determinants of Treatment Use
We assessed the role of selected demographic and clinical factors on the type of medication used
for BD during pregnancy. The prevalence of a history of suicide attempts among patients
prescribed antipsychotics in pregnancy was 45% higher than that among those taking no
psychotropic medication for BD in pregnancy. Atypical antipsychotics are often prescribed to
patients who present with suicidality. Clozapine in particular has the strongest level of evidence
for anti-suicidal effects among schizophrenia patients.197–200 This may explain why in this study,
patients with a history of suicide attempts were more often prescribed antipsychotics in
pregnancy. Because previous suicide attempts are a predictor of suicidality,201 clinicians may
potentially be prescribing antipsychotics during pregnancy to reduce suicide risk in the high-risk
patients, especially considering that pregnancy is a vulnerable period, particularly for women
with BD. We did not find a statistically significant association between history of suicide
attempts and prescriptions of antidepressants. This finding corresponds with evidence from the
literature, as antidepressants have minimal effect in helping prevent suicides.202 In fact, some
studies have reported an apparent increased risk of suicide associated with antidepressant
use,203,204 although there is still uncertainty regarding this association.86
The prevalence of recurrences in pregnancy among patients prescribed antipsychotics was 58%
higher than that among those taking no psychotropic medication for BD in pregnancy. Given that
we do not have information on the directionality of this association, it could mean one of two
things. Recurrences may have been higher as a result of the antipsychotics. One potential
explanation for this is that antipsychotics were not effective in preventing recurrence episodes in
pregnancy. One study found a higher risk of relapse from antipsychotic compared to mood
stabilizer monotherapy,205 suggesting, women should instead be treated with other drugs, most
notably, mood stabilizers. On the other hand, this association could also mean that having a
relapse in pregnancy may warrant the use of the antipsychotic medication to help alleviate the
50

symptoms as failure to do so may lead to harm to the mother and/or the fetus. According to
recent Canadian guidelines, antipsychotics are among the first treatment options that should be
prescribed, regardless of the type of BD episode.3 Thus, it may come as no surprise that there is a
higher prevalence of antipsychotic prescriptions in women that experience recurrences. The
prevalence of prior alcohol related disorders was significantly lower among women prescribed
antipsychotic alone compared to those using no treatment during pregnancy. Given that patients
with prior alcohol related disorders may also be at risk of alcohol misuse in pregnancy, clinicians
may potentially be less likely to prescribe antipsychotics in such patients to avoid risk of adverse
outcomes or interaction of both agents in the body.
Among patients who were prescribed an antidepressant only, the prevalence of obesity-related
disorders in the year prior to pregnancy was 64% lower compared to those who were using no
treatment. Similarly, one study found that depressed women using antidepressants were more
likely to be obese.206 A number of antidepressant medications have been found to be associated
with weight gain in a non-BD patient population.207–211 Therefore, it is possible that clinicians
may be cautious about prescribing antidepressant treatment in patients who already have a
history of obesity due to concerns regarding excess weight gain that may occur as a side-effect
from use. Moreover, patients may prefer to avoid antidepressants if weight gain is a personal
concern. This issue was observed in one study where a patient’s body weight was found to be a
factor that influenced the decision to initiate antidepressant treatment.212
We found that antipsychotic and antidepressant polytherapy was associated with a greater
number of psychiatric emergency department visits prior to pregnancy. Bearing in mind that
there are adverse outcomes associated with certain antipsychotics and antidepressants, women
who are prescribed polytherapy during pregnancy are likely more severe cases of BD.99 These
women may require multiple medications to help control symptom exacerbations during
pregnancy. Thus, it is not unexpected for these women to have a history of psychiatric
emergency department visits prior to pregnancy.

5.2.3 Treatment Use in Pregnancy
We failed to find a statistically significant difference in the frequency of the maternal and fetal
composite outcomes between the treatment groups. Although the association between the
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antipsychotic and antidepressant polytherapy group was not significantly associated with adverse
maternal outcomes (95% CI 0.99-3.01) per se, it is very close to being significant. For all intents
and purposes, this potentially suggests that these women are likely at a higher risk of adverse
maternal outcomes, which included venous thromboembolism, gestational diabetes, gestational
hypertension, preeclampsia or eclampsia, placental abruption, or placental infarction. Future
studies should replicate these findings to help establish the safety profile of these medications
during pregnancy.

5.3 Strengths
There are several strengths of this study. To our knowledge, this is the first study in Canada to
examine and describe drug utilization patterns in pregnant women with BD. It is worth noting
that due to ethical concerns, there is an inherent lack of research on the impact of medication use
during pregnancy. Observational studies such as this one are an important source of information.
Moreover, this is the first study to examine adverse outcomes as a result of using multiple
therapeutic drug classes prescribed for BD in pregnancy. This topic is extremely important, but
existing guidelines do not provide sufficient information. A wide range of outcomes, some of
which have not been previously examined but are clinically important, were included in this
study, making the findings of particular interest to patients, clinicians, and regulatory agencies.
This study used population-level data, which enabled us to identify a large number of cases at a
relatively low cost. Also, data on study variables were obtained from administrative databases,
which enabled us to capture the relevant information without influence of recall bias.

5.4 Limitations
There are several very important limitations that need to be taken into consideration when
interpreting the results. Administrative data have limited availability of sociodemographic
information. Despite our use of large health administrative databases spanning 12 years, our
sample size was much lower than anticipated when planning the study, which reduced the
precision of our estimates and produced relatively underpowered analyses. There are several
reasons for which we were not able to obtain a large sample from an administrative data source.
First, the method used to identify bipolar diagnosis in the population was imperfect. Ideally, the
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use of both inpatient and outpatient diagnoses would best capture all BD cases from the
population. However, since the outpatient classification code for BD also captures cases of
unipolar depression, we were limited to using inpatient codes and outpatient plus a mood
stabilizer prescription. This would have missed all cases of outpatient diagnosis combined with a
different or no BD medication. Second, the literature shows that diagnosis of BD based on
clinical assessment is not straightforward. Since most patients seek treatment for depressive
symptoms, which more often than not is the first symptom that emerges in BD patients as
opposed to mania, BD is often misdiagnosed as unipolar depression. One study found that among
1000 patients in whom BD was initially misdiagnosed, it takes on average 5.7 years to reach the
correct diagnosis from the initial misdiagnosis.213 Similarly, another reported that some patients
can remain misdiagnosed for on average 7 years.214 Not only is this a possible reason for the low
number of BD cases obtained in this study, but underdiagnoses may have drastically
underestimated the number of cases over the study period. Moreover, the study would also have
not captured women who suffer from sub-threshold BD symptoms and do not access healthcare
services.
Due to the relatively small sample size, we decided to group the outcome indicators into
composite outcomes, which also introduced several limitations. We are not able to pinpoint
exactly which outcome indicator within the group is affected. Because all the medications were
grouped into classes, with no information on individual medications, we were unable to assess a
within-class effect, and each medication may differ with respect to their mechanisms of action
and side effects. We were also not able to assess polypharmacy within class, in which more than
one agent from the same class is prescribed. As a result, generalizing the conclusions across
classes without the consideration for within-class polypharmacy may not be a good
representation of combination psychotropic treatment use. Most importantly, we assessed
outcomes during pregnancy without any consideration for medication route of administration
(oral vs. long acting injectable), dosage, duration, and trimester of medication exposure. All
these are factors that can potentially influence the outcomes of this study.
To obtain information on drug prescriptions, we used the ODB database. However, the ODB
only contains data on a subset of the general population of Ontario, which includes those who
receive support from a social assistance program (Ontario Disability Support Program and/or
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Ontario Works) or have high drug cost relative to their household income. In this study, of the
11,356 pregnancies that met the inclusion criteria, 44% were to mothers who were covered by
the ODB. People eligible for ODB tend to have greater disability, poorer overall health, and
lower socioeconomic status compared to people who pay for their medications out of pocket or
through private insurance. Thus, the trends observed in this study may not be generalizable to the
broader population of women with BD in Ontario. Nonetheless, it is still very important to
consider the impact of medication in this population given that these women are likely to be
more susceptible to adverse outcomes than healthier women. Moreover, there may have been
women who were in fact eligible under the ODB but did not meet the definition used for ODB
coverage in this study (having filled any provincially funded drug within six months prior to
conception and another either during their pregnancy or within six months after delivery) and as
a result may have been excluded from the sample.
One important limitation of the present study, which is inherent to all observational drug studies,
the possibility of confounding by indication. This type of confounding arises among a study
population of patients with the same illness, when those who are exposed to drugs are inherently
different in terms of distributions of risk factors for the study outcome from patients who are not
using the drugs.215 This potentially introduces bias because patients who are in either exposure
groups would differ in their underlying risk of study outcomes. Additionally, we did not consider
the role of immortal time bias in the analyses. Women with adverse birth outcomes related to
mortality (i.e. eclampsia) who may have died prior to delivery would have been excluded given
that to obtain the study sample, we only considered women who survived to delivery. This is a
limitation since we may not have captured effect of certain severe outcomes if it differs across
exposure status. There were also limitations to the definitions of variables used in this study. The
definition for exposure to medication and the cases of BD patients in the population has been
used in the literature, but has not been previously validated. Moreover, the exposure data on
psychotropic prescriptions was potentially not fully accurate such that it only provided
information on medications dispensed, and no information on whether the patient actually used
the prescribed regimen. Although we included two consecutive prescription fillings in the
exposure definition to try to minimize this possibility, there was still room for misclassification
errors. If a patient did not consume a medication that was recorded as prescribed during
pregnancy, they may have been incorrectly classified into the exposed group of this study. Errors
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in classification to the non-exposed group may also have occurred if a patient had not filled a
prescription in pregnancy, but may still be taking medication because they had the supply.
Additionally, some of the outcomes of interest were likely under-reported – for example, a
previous study by Joseph et al. examined the validity of diagnostic codes in CIHI-DAD and
found that respiratory distress syndrome had an estimated sensitivity of 50.9%. The authors
noted that when they added procedural codes to create a more “severe respiratory distress”
variable, agreement between the datasets reached nearly 100%. Although a similar approach was
an option for this study, it would have resulted in a much more restricted respiratory distress
syndrome variable, making the outcome rarer and less clinically relevant. Furthermore,
validation studies have proposed more sensitive approaches to capturing certain outcome data
from administrative databases, specifically when a second source is added. Alotaibi et al. sought
to evaluate the accuracy of using ICD diagnostic codes combined with imaging codes for
identifying venous thromboembolism. They found that using imaging codes concurrently
resulted in the outcome being more accurately captured when compared to physician diagnosis
obtained by chart review.216 Similarly, another study found that the addition of venous
thromboembolism treatment codes along with diagnostic codes improved the estimated positive
predicted value from 72% to 91%.217 One other study assessed venous thromboembolism using
emergency department diagnosis and found a moderate positive predicted value.218 Although this
may not be the best source to rely on for venous thromboembolism, using it concurrently with
hospital discharge codes may demonstrate higher accuracy.
Some important covariates identified by the literature review were not included in the analysis,
as we were restricted to those available in the ICES databases. These variables include poor
prenatal care, smoking status, and BMI; all which are associated with poor outcomes.
Additionally, we were only able to capture diagnosed alcohol and substance related disorders
that came to the attention of healthcare services in Ontario. Despite this limitation, however, in
this thesis we controlled for a wider and more detailed set of covariates than that considered by
previous studies in this area of research.
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5.5 Future Directions
Future research is needed to better understand the trends in treatment use during pregnancy and
safety of medication use across drug classes among women with BD. There are still many
unanswered questions regarding concomitant treatment use during pregnancy. Pharmacokinetic
studies of multiple psychotropic agent use in pregnant BD patients are essential to determine
how these medications may contribute to potential maternal and fetal risks. Future populationbased cohort studies should also consider stratifying pregnancy outcomes according to the
trimester of medication exposure. This is because the risk of most pregnancy outcomes may
differ based on when during the perinatal period the medication was administered to the mother.
Exposure in the first trimester is commonly a concern for teratogenicity and fetal anomalies
given that the fetal organs undergo development in that time period, whereas exposure in the
second and third trimester is related to fetal growth and development of adverse pregnancy
outcomes. Moreover, it may be worthwhile to include treatment patterns before and after the
perinatal period as well. This would allow exploration of treatment modifications as a result of
pregnancy and delivery in new mothers with BD. Furthermore, while this thesis focused
primarily on short-term outcomes (within one year of delivery, at a maximum), it would be
important to determine long-term impact in patients using psychotropic drugs for BD during
pregnancy. Clinicians may benefit from this knowledge to guide on-going care of mothers and
their children past the period of gestation.

5.6 Conclusion
Awareness of adverse drug events is extremely important in clinical settings for safe prescribing
practices. Our study findings suggest that a substantial proportion of women are using
psychotropic medications for BD in pregnancy, most commonly antipsychotic monotherapy,
antidepressant monotherapy, and antipsychotic-antidepressant polytherapy. It is important to
recognize that prescribing patterns observed in this study do not match the recommendations of
the Canadian guidelines. Due to the remaining uncertainty of risks from use of multiple
psychotropic drug classes during pregnancy, limited recommendations can be made. However,
results from this study are still of interest, providing a measure of risk in an area of research
where there is limited evidence and few estimates of risk exist. Of importance is that we found
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no evidence to suggest harm which is a reassuring finding in support of medication use. Caution
should be exercised when prescribing treatment to mothers with BD, especially those considered
high-risk for adverse pregnancy outcomes.
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Appendix A. Literature review database search strategy
Concept

Medline-Ovid

Embase

PsycINFO

CINAHL

Keywords

Bipolar
Disorder

Bipolar Disorder

exp bipolar
disorder/

MAINSUBJECT.
EXACT("Bipolar
Disorder")

(MH "Bipolar
Disorder+")

Pregnancy and
Pregnancy
Complications

pregnancy/ or
gravidity/ or
pregnancy
outcome/

therapeutics/ or
drug therapy/ or
drug
prescriptions/ or
polypharmacy/ or
exp Psychotropic
Drugs/

MJMAINSUBJE
CT.EXACT("Pre
gnancy") OR
MAINSUBJECT.
EXACT.EXPLO
DE("Pregnancy
Outcomes")
MJMAINSUBJE
CT.EXACT("Dru
gs") OR
MJMAINSUBJE
CT.EXACT("Dru
g Therapy")

(MH
"Pregnancy+") OR
(MH "Pregnancy
Complications+")

Psychotropic
Treatment and
Combination
Treatment

Pregnancy/ OR
exp pregnancy
OR trimesters/
OR exp
pregnancy,
multiple/ OR
pregnant women/
exp psychotropic
agent/ or exp
combination drug
therapy/or exp
drug therapy/ or
monotherapy/ or
polypharmacy/

Bipolar disorder* OR bipolar
depression OR mania* OR
maniac OR manic
OR hypermani* OR
hypomani* OR bipolar
affective disorder OR manic
depression OR bipolar
spectrum disorder OR bipolar
mood disorder OR manic
depressive syndrome OR
manic depressive syndrome
Pregnant OR pregnancy OR
pregnancies OR gestation* OR
pregnant women OR child
bearing OR childbearing

(MH "Psychotropic
Drugs+")

Psychotropic treatment* OR
psychotropic medication* OR
drug treatment* OR drug
therap* OR combination
treatment* OR polypharmacy
OR polytherap* OR
monotherap* OR drug agent*
OR drug class*
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Appendix B. Copy of Western REB approval notice
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Appendix C. List of included medications by drug classes
Therapeutic Class
Mood Stabilizers

Antipsychotics

Sub-Class
Lithium Agents

Medications
Lithium agents

Anticonvulsants

Carbamazepine, Clobazam, Divalproex Sodium, Eslicarbazepine Acetate,
Ethosuximide, Gabapentin, Lacosamide, Lamotrigine, Levetiracetam,
Carbonate, Methsuximide, Oxcarbazepine, Perampanel, Phenytoin
(Diphenylhydantoin), Phenytoin (Diphenylhydantoin) Sodium, Pregabalin,
Primidone, Topiramate, Valproate Sodium, Valproic Acid, Vigabatrin,
Flupentixol Decanoate, Flupentixol Dihydrochloride, Fluphenazine Hcl,
Haloperidol, Haloperidol Decanoate, Loxapine Succinate , Pericyazine,
Perphenazine, Pimozide, Prochlorperazine, Thiothixene, Trifluoperazine,
Aripiprazole, Asenapine, Clozapine, Lurasidone Hydrochloride, Olanzapine,
Paliperidone, Paliperidone Palmitate, Quetiapine, Risperidone, Ziprasidone
HCL Monohydrate
Amitriptyline, Bupropion HCL, Citalopram Hydrobromide, Clomipramine
HCL, Desipramine, Doxepin HCL, Imipramine, Mirtazapine, Moclobemide,
Nortriptyline, Tranylcypromine Sulfate, Trimipramine
Fluoxetine HCL, Paroxetine HCL, Escitalopram, Sertraline HCL
Duloxetine, Venlafaxine HCL
Phenelzine Sulfate
Trazodone Hydrochloride
Bromazepam, Chlordiazepoxide, Clorazepate Dipotassium, Diazepam,
Hydroxyzine Hcl, Lorazepam, Oxazepam,

Typicals (First Generation)

Atypicals (Second
Generation)
Antidepressants

Tricyclics

Antianxiety

SSRIs
SNRIs
MAOIs
Others
Benzodiazepines
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Appendix D. All study variables and definitions with description of scale of measurement originally obtained from ICES and
recoded for analysis
Scale of Measurement Description
Variables

Variable Definition

Original

Analysis

Exposure and Baseline Variables
Mood stabilizer treatment

Mood stabilizer filled between the
conception and delivery date

1. Prescribed mood
stabilizers
0. No mood stabilizers

1. Prescribed mood
stabilizers
0. No mood stabilizers

Total number of mood stabilizer
prescriptions

If prescribed mood stabilizers (1), list the
total number of prescriptions filled during
the period of pregnancy
Antipsychotic filled between the
conception and delivery date

1-#

1-#

1. Prescribed
antipsychotic
0. No antipsychotic

If prescribed antipsychotic (1), list the
total number of prescriptions filled during
the period of pregnancy
Antianxiety filled between the conception
and delivery date

1-#

1. Prescribed
antipsychotic
0. No antipsychotic
prescribed
1-#

1. Prescribed anxiolytics
0. No anxiolytics
prescribed

1. Prescribed anxiolytics
0. No anxiolytics
prescribed

If prescribed antianxiety (1), list the total
number of prescriptions filled during the
period of pregnancy
Antidepressant filled between the
conception and delivery date

1-#

1-#

1. Prescribed
antidepressants
0. No antidepressants
prescribed

1. Prescribed
antidepressants
0. No antidepressants
prescribed

Antipsychotic treatment

Total number of antipsychotic
prescriptions
Antianxiety treatment
(anxiolytics)
Total number of antianxiety
prescriptions
Antidepressant treatment
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Total number of antidepressant
prescriptions

If prescribed antidepressant (1), list the
total number of prescriptions filled during
the period of pregnancy
Which method was used to diagnose
individual with bipolar disorder

1-#

1-#

1. DAD or OHMRS
hospitalizations
2. Outpatient with
prescription

1. DAD or OHMRS
hospitalizations
2. Outpatient with
prescription

Age

Age at delivery

1. 13-19
2. 20-29
3.30-39
4.40-50

1. 13-19
2. 20-29
3.30-39
4.40-50

Parity

Number of previous live births

1-#

Income

Rank individual income levels by level of
marginalization

Baby's gender

Sex at delivery

Year delivery

Year of delivery

1. least
marginalized to
5. most marginalized
1. Male
2. Female
Any year between 20022014

1. 0
2. 1
3. 2+
1. least
marginalized to
5. most marginalized
1. Male
2. Female
Any year between 20022014

1. Diagnosed with
obesity
0. No diagnosis of
obesity
1. Diagnosed with
alcohol related disorders
0. No diagnosis of
alcohol related disorders

1. Diagnosed with
obesity
0. No diagnosis of
obesity
1. Diagnosed with
alcohol related disorders
0. No diagnosis of
alcohol related disorders

Source of diagnosis

Demographic Variables

Pre-morbid Conditions
Obesity

Patient diagnosed up to one year prior to
conception and/or in pregnancy

Alcohol related disorders

Patient diagnosed with alcohol related
disorders in the year prior to conception
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Substance related disorders

Patient diagnosed with substance related
disorders in the year prior to conception

Lifetime anxiety disorder
(includes anxiety neurosis,
hysteria, neurasthenia,
obsessive compulsive neurosis,
reactive depression)
Attempted suicide

Diagnosed any time prior to conception

History of gestational diabetes

Patient diagnosed within five years prior
to conception

Pre-existing hypertension

Patient diagnosed within five years prior
to conception

Pre-existing diabetes

If patient has pre-existing diabetes

Previous pregnancy with preeclampsia

Diagnosis within 5 years prior to
conception

Patient had a record of attempted suicide
any time before conception

1. Diagnosed with
substance related disorder
0. No diagnosis of
substance related
disorders
1. Diagnosed with
lifetime anxiety disorder
0. No diagnosis of
lifetime anxiety disorder

1. Diagnosed with
substance related disorder
0. No diagnosis of
substance related
disorders
1. Diagnosed with
lifetime anxiety disorder
0. No diagnosis of
lifetime anxiety disorder

1. History of suicide
attempt
0. No history of suicide
attempt
1. Diagnosed with
gestational diabetes
0. No diagnosis of
gestational diabetes
Missing: If no previous
pregnancy
1. Diagnosed with
hypertension
0. No diagnosis of
hypertension
1. Pre-existing diabetes
0. No pre-existing
diabetes
1. Diagnosed with
preeclampsia
0. No diagnosis of
preeclampsia

1. History of suicide
attempt
0. No history of suicide
attempt
1. Diagnosed with
gestational diabetes
0. No diagnosis of
gestational diabetes
Missing: If no previous
pregnancy
1. Diagnosed with
hypertension
0. No diagnosis of
hypertension
1. Pre-existing diabetes
0. No pre-existing
diabetes
1. Diagnosed with
preeclampsia
0. No diagnosis of
preeclampsia
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Previous pregnancy with deep
vein thrombosis and pulmonary
embolism
(venous thromboembolism
disease)

Diagnosis within 5 years prior to
conception

Previous preterm birth

A previous birth from the same mother
diagnosed with preterm birth

1. Diagnosed with
venous thromboembolism
disease
0. No diagnosis of
venous thromboembolism
disease
1. History of preterm
birth
0. No history of preterm
birth or no previous
delivery

1. Diagnosed with
venous thromboembolism
disease
0. No diagnosis of
venous thromboembolism
disease
1. History of preterm
birth
0. No history of preterm
birth or no previous
delivery
1. Recurrence episode
0. No recurrence episode
1. Rapid repeat
pregnancy
0. Rapid repeat
pregnancy/no recent
hospitalizations for
delivery
1. Diagnosed with
placental previa
0. No diagnosis of
placental previa
00-45

Current Pregnancy or Delivery Variables
Recurrence of a mood episode

Placental Previa

Diagnosis during the gestation period

Gestational weeks

Newborn’s gestational weeks at delivery

1. Recurrence episode
0. No recurrence episode
1. Rapid repeat
pregnancy
0. Rapid repeat
pregnancy/no recent
hospitalizations for
delivery
1. Diagnosed with
placental previa
0. No diagnosis of
placental previa
00-45

Newborn’s weight

Newborn’s weight at delivery

050-6000 grams

050-6000 grams

Epidural

Use of epidural at delivery

1. Epidural used
0. No epidural used

1. Epidural used
0. No epidural used

Previous record of inpatient psychiatric
admission

1. Yes
0. No

1. Yes
0. No

Rapid repeat pregnancy

Diagnosis of bipolar disorder or
depression during the gestation period
Conception within 6 months of a previous
delivery

Service Use Variables
Maternal psychiatric hospital
admission
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Maternal emergency department
visit

Number of previous psychiatric
emergency room visits in the year prior to
conception
If diagnosis of bipolar disorder was with
hospitalization, total number of
hospitalizations that occurred prior to
pregnancy

1-#

1-#

1-#

1-#

Delivery with forceps or
ventouse

Newborn was delivered by cesarean
delivery
Newborn delivery was an instrumental
birth

Labour induction

Labour was artificially induced

Episiotomy or delivery with
severe tear
Maternal Outcomes (pregnancy)

Perineal trauma from an episiotomy or 3rd
or 4th degree tear at delivery

1. Cesarean delivery
0. No cesarean delivery
1. Instrumental delivery
0. No instrumental
delivery
1. Induced delivery
0. No induced delivery
1. Perineal trauma
0. No perineal trauma

1. Cesarean delivery
0. No cesarean delivery
1. Instrumental delivery
0. No instrumental
delivery
1. Induced delivery
0. No induced delivery
1. Perineal trauma
0. No perineal trauma

Gestational Diabetes

Diagnosis between conception and
delivery

Number of previous bipolar
hospitalizations

Outcome Measures
Delivery Outcomes
Cesarean delivery

Gestational Hypertension

Preeclampsia and eclampsia
(PREE)

1. Diagnosed with
gestational diabetes
0. No diagnosis of
gestational diabetes
Diagnosis between conception and
1. Diagnosed with
delivery. Except for women who have pre- gestational hypertension
existing diabetes (record in Ontario
0. No diagnosis of
Diabetes Dataset)
gestational hypertension
Patient diagnosed between 20 week post1. Diagnosed with PREE
conception and delivery
0. No diagnosis of PREE

1. Diagnosed with
gestational diabetes
0. No diagnosis of
gestational diabetes
1. Diagnosed with
gestational hypertension
0. No diagnosis of
gestational hypertension
1. Diagnosed with PREE
0. No diagnosis of PREE
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Deep vein thrombosis and
pulmonary embolism
(venous thromboembolism
disease)

Patient diagnosed with during the
gestation period

1. Diagnosed with
venous thromboembolism
disease
0. No diagnosis of
venous thromboembolism
disease
1. Diagnosed with
placental abruption
0. No diagnosis of
placental abruption
1. Diagnosed with
placental infarction
0. No diagnosis of
placental infarction

1. Diagnosed with
venous thromboembolism
disease
0. No diagnosis of
venous thromboembolism
disease
1. Diagnosed with
placental abruption
0. No diagnosis of
placental abruption
1. Diagnosed with
placental infarction
0. No diagnosis of
placental infarction

Placental Abruption

Patient diagnosed during the gestation
period

Placental Infarction

Patient diagnosed during the gestation
period

Flag if maternal death occurred after 42
days of delivery but within the year
Flag if patient transferred to ICU at
delivery

1. Maternal mortality
0. No maternal mortality
1. Transferred to ICU
0. No transfer to ICU

1. Maternal mortality
0. No maternal mortality
1. Transferred to ICU
0. No transfer to ICU

Diagnosed if baby is delivered before 37
weeks of gestation
If newborn’s birthweight is below the 10th

N/A (derived)

1. Preterm birth
0. No preterm birth
1. Diagnosed with SGA
0. No diagnosis of SGA
1. Diagnosed with LGA
0. No diagnosis of LGA
1. Diagnosed with
neonatal adaption
syndrome
0. No diagnosis of
neonatal adaption
syndrome

Maternal Outcomes (post pregnancy)
Late maternal mortality
Transfer to ICU
Neonatal Outcomes
Preterm birth
Small for gestational age (SGA)
Large for gestational age (LGA)
Neonatal adaption syndrome

percentile for their gestational age and sex
If newborn’s birthweight is above the 90th
percentile for their gestational age and sex
Newborn diagnosed up to one year after
delivery

N/A (derived)
N/A (derived)
1. Diagnosed with
neonatal adaption
syndrome
0. No diagnosis of
neonatal adaption
syndrome
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Respiratory distress syndrome

Newborn diagnosed up to one year after
delivery

Seizure

Newborn diagnosed up to one year after
delivery
Newborn diagnosed within 90 days of
delivery
Newborn diagnosed within 90 days of
delivery
Newborn diagnosed within 4 weeks of
delivery

Sepsis
Intraventricular Hemorrhage
(IVH)
Infection

Neonatal Mortality

Flag if neonatal death occurred within 27
days after delivery

1. Diagnosed with
respiratory distress
syndrome
0. No diagnosis of
respiratory distress
syndrome
1. Diagnosed with seizure
0. No diagnosis of seizure
1. Diagnosed with sepsis
0. No diagnosis of sepsis
1. Diagnosed with IVH
0. No diagnosis of IVH
1. Diagnosed with
infection
0. No diagnosis of
infection
1. Neonatal mortality
0. No neonatal mortality

1. Diagnosed with
respiratory distress
syndrome
0. No diagnosis of
respiratory distress
syndrome
1. Diagnosed with seizure
0. No diagnosis of seizure
1. Diagnosed with sepsis
0. No diagnosis of sepsis
1. Diagnosed with IVH
0. No diagnosis of IVH
1. Diagnosed with
infection
0. No diagnosis of
infection
1. Neonatal mortality
0. No neonatal mortality

1. Diagnosis of
congenital malformation
0. No diagnosis
congenital malformations
1. Still birth
0. No still birth

1. Diagnosis of
congenital malformation
0. No diagnosis
congenital malformations
1. Still birth
0. No still birth

1. Patient readmitted
0. Patient not readmitted

1. Patient readmitted
0. Patient not readmitted

1. Patient readmitted
0. Patient not readmitted

1. Patient readmitted
0. Patient not readmitted

Fetal Outcomes
Congenital Malformations

Newborn diagnosed with at least one
anomaly at any point within one year after
delivery

Stillbirth

Flag if fetal death occurred after 20
gestational weeks

Service Use Outcomes
Readmission (mental health) ≤ 7
days
Readmission (mental health) 1 to
12 weeks

Flag if patient readmitted for mental
health related concerns within 7 days of
discharge date after delivery
Flag if patient readmitted for mental
health related concerns within 12 weeks of
discharge date after delivery
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Appendix E. All study variables and their classification codes used to identify event in health administrative databases with
description of potential issues with measurement
Variables
Cohort
Bipolar Disorder Diagnosis

Classification Codes

Potential Issues with Measurement

1. A discharge diagnosis of bipolar disorder in the Ontario
Mental Health Reporting System (OMHRS)

Missing the subset of the population
who are diagnosed in outpatient
clinician settings without a
prescription

OMHRS codes: 29600, 29601, 29602, 29603, 29604, 29605,
29606, 29640, 29641, 29642, 29643, 29644, 29645, 29646,
29650, 29651, 29652, 29653, 29654, 29655, 29656, 29660,
29661, 29662, 29663, 29664, 29665, 29666, 29670, 29680,
29689
2. A diagnosis of bipolar disorder in the Discharge Abstracts
Database (CIHI-DAD)
DAD ICD-9: 2960, 2961, 2964, 2965, 2966, 2967, 2968
DAD ICD-10: F300, F301, F302, F308, F309, F310, F311,
F312, F313, F314, F315, F316, F317, F318, F319
3. OHIP outpatient diagnoses of a mood disorder and at least
one prescription of a mood stabilizer medication that must
occur after the OHIP diagnosis
OHIP fee code 296, all non-lab services where location is
office, phone, long-term care, or home and diagnosis can be
made by any physician type.
Baseline Variables
Pre-morbid Conditions
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Obesity

ICD 10 E66 or ICD 9 278.00-278.02 or 2 OHIP 278

Alcohol related disorders

ICD 10 F10 or ICD 9 291, 303 or 1 OHIP 303 or OMHRS
30390

Substance related disorders

ICD 10 F11-F19 or ICD 9 304, 305 or 1 OHIP 304, 305 or
OMHRS 30400, 30410, 30420, 30430,30440, 30450, 30460,
30480, 30490,30510

Lifetime anxiety disorder
(includes anxiety neurosis,
hysteria, neurasthenia,
obsessive compulsive
neurosis, reactive
depression)
Attempted suicide

ICD 10 F41 F42 F48.0 or ICD 9 300.00-300.03, 300.09, 300.3,
300.5 or 2 OHIP 300 or OMHRS 30000, 30001, 30002, 30030

History of gestational
diabetes
Previous pregnancy with
pre-eclampsia
Previous pregnancy with
deep vein thrombosis and
pulmonary embolism
(venous thromboembolism
disease)
History of renal disease

ICD 10-CA E10, E11, E13, E14, 024.8 or ICD 9-CM 648.8 or
1 OHIP 250
ICD 10-CA O14 or ICD 9-CM 642.40-642.43, 642.50-642.53

ICD 10 X60-X84 or ICD 9 E950-E954

Obesity likely not adequately
captured because BMI is not
recorded in database. This variable
only captured obesity that is formally
diagnosed
Alcohol use likely not adequately
captured because alcohol intake is
not recorded in database. This
variable only captures alcohol related
disorders
Substance use likely not adequately
captured because substance abuse is
not recorded in database. This
variable only captures substance
related disorders

This will not capture attempts that
are not formally recorded

ICD 10-CA 022.3, O88.2, I80, I26 or ICD 9-CM 671.30671.33, 673.20-673.23, 415.1, 451 or 1 OHIP 451, 415

ICD 10-CA I12 or ICD 9-CM 403.0 or 2 OHIP 403
93

Antiphospholipid syndrome ICD 10-CA D68.6 or ICD 9-CM 289.81
(AP)
Current Pregnancy or Delivery Variables
Recurrence of a mood
1 OHIP 296 or
episode
1. A discharge diagnosis of bipolar disorder in the Ontario
Mental Health Reporting System (OMHRS)

Will not capture recurrences that are
not reported

OMHRS codes: 29600, 29601, 29602, 29603, 29604, 29605,
29606, 29640, 29641, 29642, 29643, 29644, 29645, 29646,
29650, 29651, 29652, 29653, 29654, 29655, 29656, 29660,
29661, 29662, 29663, 29664, 29665, 29666, 29670, 29680,
29689
2. A diagnosis of bipolar disorder in the Discharge Abstracts
Database (CIHI-DAD)

Placental Previa
Epidural
Service Use Variables
Maternal psychiatric
hospital admission
Maternal emergency
department visit
Number of previous bipolar
hospitalizations

DAD ICD-9: 2960, 2961, 2964, 2965, 2966, 2967, 2968
DAD ICD-10: F300, F301, F302, F308, F309, F310, F311,
F312, F313, F314, F315, F316, F317, F318, F319
ICD 10-CA O44 or ICD 9-CM 641.00-641.03 or 1 OHIP 641
CIHI-DAD: CCI 5.LD.20.HA-P1 or CIHI-DAD: CCP 16.91
ICD 10 F00-F99, G30, G31, R54 or ICD 9 290-319
NACRS DX10CODE: ICD 10 F00-F99, G30, G31, R54
1. A discharge diagnosis of bipolar disorder in the Ontario
Mental Health Reporting System (OMHRS)
OMHRS codes: 29600, 29601, 29602, 29603, 29604, 29605,
29606, 29640, 29641, 29642, 29643, 29644, 29645, 29646,
29650, 29651, 29652, 29653, 29654, 29655, 29656, 29660,
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29661, 29662, 29663, 29664, 29665, 29666, 29670, 29680,
29689
2. A diagnosis of bipolar disorder in the Discharge Abstracts
Database (CIHI-DAD)
DAD ICD-9: 2960, 2961, 2964, 2965, 2966, 2967, 2968
DAD ICD-10: F300, F301, F302, F308, F309, F310, F311,
F312, F313, F314, F315, F316, F317, F318, F319
Outcome Measures
Delivery Outcomes
Cesarean delivery

Delivery with forceps or
ventouse
Labour induction

CIHI-DAD: CCI 5.MD.60 or CIHI-DAD: CCP 86.0 to 86.2,
86.8 or 86.9
CIHI-DAD: CCI 5.MD.53,54,55, 5MD56PC/PF/PJ or CIHIDAD: CCP 84.0, 84.1, 84.2, 84.3, 84.7
CIHI-DAD: CCI 5.AC.30 or CIHI-DAD: CCP 85.5

Does not distinguish between
elective and medically necessary
procedure

Will capture labour inductions that
were purposeful due to patient
preferences

Episiotomy or delivery with
severe tear

CIHI-DAD: CCI 5.MD.50.GH, 5.MD.53.KS/JE/KL/KN/KJ,
5.MD.54.KJ/KL/KN/NF, 5.MD.55.KN/KL/KJ/KR,
5MD56PA/PB/PC/PD/PE/PF/PG/PH/PJ, 5PC80JN, 5PD13SB
or CIHI-DAD: CCP 85.7
Maternal Outcomes (pregnancy)
Gestational Diabetes
ICD 10-CA E10, E11, E13, E14, 024 or ICD 9-CM 648.8 or 1
OHIP 250
Gestational Hypertension
ICD 10-CA O13, I10, I15 or ICD 9-CM642.30-642.33, 642.90642.93
Except when woman is present in the ICES HYPER database
Preeclampsia and eclampsia ICD 10-CA O14, O15 or ICD 9-CM 642.40-642.43, 642.50642.53, 642.60-642.63
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Deep vein thrombosis and
ICD 10-CA 022.3, O88.2, I80, I26 or ICD 9-CM 671.30pulmonary embolism
671.33, 673.20-673.23, 415.1, 451 or 1 OHIP 451, 415
(venous thromboembolism
disease)
Placental Abruption
ICD 10-CA O45 or ICD 9-CM 641.20-641.23 or 1 OHIP 641
Placental Infarction
ICD 10-CA O43.81 or ICD 9-CM656.80-656.83
Maternal Outcomes (post pregnancy)
Transfer to ICU
DAD variable "SCU". Includes values:
10 = Medical Intensive Care Nursing Unit
20 = Surgical Intensive Care Nursing Unit
25 = Trauma Intensive Care Nursing Unit
30 = Combined Medical/Surgical Intensive Care Nursing Unit
Neonatal Outcomes
Neonatal adaption syndrome ICD 10-CA P96.1 or ICD 9-CM 779.5
Respiratory distress
syndrome
Seizure
Sepsis
Intraventricular Hemorrhage
Infection

Not able to capture reason for the
ICU admission; can unrelated to
exposure of interest

ICD 10-CA P22.0 or ICD 9-CM 769
ICD 10-CA P90 or ICD 9-CM 779.0 or 1 OHIP 780
ICD 10-CA P36,A40, A41 or ICD 9-CM 771, 038.0, 038.2,
038.2, 038.1, 038.4, 038.3, 038.8, 038.9
ICD 10-CA I61.5, P10.2, P52 or ICD 9-CM 431, 772.0-772.2
ICD 10-CA P23, P35, P37 or ICD 9-CM 770.0, 771 or 1 OHIP
486,056,054,070,052,079,010,011,012,015,017,130,112

Fetal Outcomes
Congenital Malformations

ICD 10-CA Q.00-Q.89 or ICD 9-CM 740-757, 759 or 1 OHIP
743,744,746.748,750,755,759
Psychiatric Readmission Outcome
Readmission (mental health) The most responsible diagnosis of:
≤ 7 days
CIHI-DAD ICD 10 F00.X-F99.X, G30.X, G31.X, R54.X or
ICD 9 290-319
Readmission (mental health) The most responsible diagnosis of:
1 to 12 weeks
CIHI-DAD ICD 10 F00.X-F99.X, G30.X, G31.X, R54.X or
ICD 9 290-319
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Appendix F. Evidence of association between study covariates and composite outcomes
Composite
Outcome
Neonatal
Outcomes

Fetal Outcomes

Description of Covariate Association
Age
 Increased risk of preterm birth219
 Maternal age of 30-40 increases risk of large for gestational age babies220
 Maternal age at pregnancy is a risk factor for the development of respiratory distress syndrome in neonates 221
 Risk of neonatal seizures increases with age222,223
Parity
 First time pregnancy increases the risk of a preterm birth224
 Two or more births associated with higher risk of large for gestational age babies220
 First pregnancy or higher order births are associated with higher risk of maternal mortality225
 Increases risk of sepsis is neonate226
 Neonates of women with no previous birth and with 5 or more previous births are at risk of neonatal seizures222
History of a preterm birth
 Increases risk of a future preterm birth224
Placental Previa
 Increases risk of preterm birth227
Close conception
 Conception less than 6 months after a live birth increases risk of a preterm birth and newborn being small for
gestational age 228,229
Income
 Low income increases risks of neonatal mortality230
Substance Use
 Misuse of drugs is associated with higher risk of neonatal adaption syndrome231
Obesity
 Maternal obesity is associated with higher risk of neonatal seizures222
Diabetes
 Maternal diabetes diagnosis is associated with increased risk of neonatal seizures222
Age
 Pregnancy in women of advanced maternal age (>35) are at increased risk of stillbirths232
Parity
 First birth and 3 or more previous births are both associated with a higher risk of stillbirths233
Income
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Maternal
Outcomes
(pregnancy)

 Low socioeconomic status is associated with increased risks of birth defecnts234
Substance abuse
 Illicit drug use increases risk of stillbirth pregnancies235
Obesity
 Increases risk of a stillbirth232,233
 Risk of congenital anomalies increases in obese pregnant patients236
Diabetes
 Increases risk of congenital anomalies in newborn236
 Pre-existing diabetes has been associated with an increased risk of stillbirths233
Alcohol
 Use in pregnancy increases risk of congenital anomalies236
Age
 Pregnancy in women of increasing age is associated with risk of gestational diabetes in pregnancy237,238
 Pregnancy in older age is associated with a higher risk of gestational hypertension239
 Risk of eclampsia increases in young (<20) and older (≥35) mothers240
 Risk of placental abruption increases in in young (<20) and older (≥35) mothers241
Income
 Women of a lower socioeconomic status are at a higher risk of developing eclampsia240
Alcohol
 Use of alcohol in pregnancy increases risk of placental abruption in pregnancy241
Substance Use
 Substance abuse is associated with placental abruption242
Obesity
 Maternal obesity increases risk of venous thromboembolism243
 Pre-pregnancy obesity is associated with risk of gestational diabetes in pregnancy237,244
 Pre-pregnancy obesity was associated with the development of gestational hypertension238,239,244,245
 Pre-pregnancy obesity is associated with preeclampsia and eclampsia in pregnancy 240,244–248
Diabetes
 Women with a history of diabetes were at risk of developing gestational diabetes in pregnancy237
 Women with type 1 diabetes were at a higher risk of developing preeclampsia245
 Maternal diabetes increases risk of placental abruption in pregnancy241
Parity
 Women with no previous births were at a higher risk of developing gestational hypertension in pregnancy239
 Women with no previous births had a higher than average risk of developing preeclampsia and eclampsia 240,246,247,249
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Labour and
Delivery
Outcomes

 Giving birth to 3 or more children increases risk of placental abruption in pregnancy241
History of preeclampsia
 Women who had a preeclampsia diagnosis in a previous pregnancy were at an increased risk of a subsequent one247
 History of preeclampsia increases risk of a placental abruption in pregnancy241
Hypertension
 Hypertension diagnosed prior to pregnancy is associated with a high risk of preeclampsia/eclampsia in women248
 Hypertension increases risk of placental abruption in pregnant women241
Placental Previa
 Placental previa in pregnancy increases the risk of placental abruption241
Previous history of gestational diabetes
 Gestational diabetes in prior pregnancies is a risk factor for the development of gestational diabetes238
Age
 Increasing maternal age is associated with increased risks of a cesarean delivery250
 Pregnancy in age over 35 increases the risk of a forceps/ventouse delivery251
 Increasing age is associated with an episiotomy in delivery252
Income
 Women in Canada’s lowest-income neighbourhoods are significantly more likely to have caesarean

sections than those in the highest-income areas253

Psychiatric
Readmission

Parity
 Decreasing parity is associated with an increased risk of cesarean section delivery250
 A woman who is giving birth to the first child is at a higher risk of experiencing perineal trauma254–256
Obesity
 Obesity is significantly associated with an increased cesarean delivery rate244,257
Diabetes
 Pre-pregnancy diagnosis of diabetes is associated with a cesarean delivery250
Epidural Use
 Use of epidural in pregnancy has been associated with cesarean delivery250
 Epidural use is a strong risk factors for forceps/ventouse delivery in women251
Age
 Younger age is associated with increased risk of readmission258
Income
 Low income is associated with a higher risk of hospital readmission258
Previous Hospitalization
 A previous hospitalization or number of previous psychiatric hospitalizations is associated with an increased risk of
readmission258–260
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Suicide
 Suicide ideation is associated with risk of readmission261
Recurrence
 Experiencing recurrence episodes during pregnancy may be severe enough to warrant readmission
Alcohol
 History of alcohol abuse has been shown to increase risk of psychiatric readmission260
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Appendix G. Unadjusted and adjusted risk ratios for maternal outcomes
Unadjusted Estimates
RR (95% CI)

Adjusted Estimates
RR (95% CI)

Treatment: No drug

Reference

Reference

Antipsychotic Only

1.12 (0.82-1.54)

1.04 (0.80-1.35)

Antidepressant Only

0.92 (0.54-1.56)

0.94 (0.60-1.49)

Antipsychotic and Antidepressant Polytherapy

2.00 (1.19-3.38)*

1.73 (0.99-3.01)

Age Groups: 13-19

0.74 (0.44-1.23)

0.74 (0.48-1.33)

20-29

Reference

Reference

30-39

1.34 (1.08-1.66)*

1.48 (1.19-1.83)*

40-50

1.54 (0.93-2.56)

1.93 (1.11-3.36)*

Number of Previous Births: 0

Reference

Reference

1

0.88 (0.69-1.14)

0.69 (0.54-0.88)*

2+

1.03 (0.81-1.32)

0.78 (0.61-1.00)

Income: 1- Lowest neighbourhood income quintile

Reference

Reference

2

1.13 (0.86-1.49)

1.08 (0.84-1.39)

3

1.70 (1.29-2.25)*

1.42 (1.09-1.86)*

4

1.23 (0.87-1.73)

1.22 (0.89-1.67)

5

1.15 (0.77-1.74)

1.22 (0.89 -1.30)

Obesity

1.59 (1.24-2.04)*

1.52 (1.19-1.95)*

History of Gestational Diabetes

1.76 (1.16-2.66)*

1.46 (0.96-2.23)

Pre-existing Diabetes

0.58 (0.25-1.38)

0.49 (0.22-1.13)

Pre-existing Hypertension

1.82 (1.07-3.07)*

0.83 (0.53-1.30)

Previous Pregnancy with Preeclampsia

2.35 (1.08-5.12)*

3.39 (1.44-8.00)*

Prior Alcohol Related Disorders

1.03 (0.81-1.31)

0.95 (0.75-1.20)

Prior Substance Related Disorders

0.89 (0.73-1.10)

0.85 (0.70-1.04)

Placental Previa

14.49 (12.72-16.51)*

14.41 (12.26-16.93)*

* p< 0.05
CI=confidence interval
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Appendix H. Unadjusted and adjusted risk ratios for neonatal outcomes
Unadjusted Estimates
RR (95% CI)

Adjusted Estimates
RR (95% CI)

Treatment: No drug

Reference

Reference

Antipsychotic Only

1.04 (0.92-1.17)

1.02 (0.92-1.14)

Antidepressant Only

1.02 (0.85-1.22)

0.98 (0.83-1.16)

Antipsychotic and Antidepressant Polytherapy

1.17 (0.92-1.49)

1.11 (0.89-1.39)

Age Groups: 13-19

0.80 (0.67-0.95)*

0.85 (0.72-1.00)

20-29

Reference

Reference

30-39

0.99 (0.92-1.08)

0.99 (0.91-1.08)

40-50

1.03 (0.84-1.27)

1.05 (0.85-1.28)

Number of Previous Births: 0

Reference

Reference

1

0.97 (0.88-1.06)

0.93 (0.85-1.02)

2+

0.99 (0.90-1.08)

0.96 (0.87-1.05)

Income: 1 - Lowest neighbourhood income quintile

Reference

Reference

2

0.96 (0.87-1.06)

0.98 (0.89-1.07)

3

0.97 (0.87-1.08)

0.98 (0.88-1.10)

4

0.97 (0.86-1.10)

0.96 (0.86-1.08)

5

1.00 (0.87-1.15)

1.04 (0.90-1.19)

Previous Delivery with Preterm Birth

2.61 (2.49-2.73)*

2.65 (2.51-2.78)*

Obesity

1.05 (0.94-1.16)

0.99 (0.89-1.10)

Prior Substance Related Disorders

1.17 (1.08-1.26)*

1.14 (1.06-1.22)*

Rapid Repeat Pregnancy

0.98 (0.69-1.38)

0.88 (0.64-1.21)

Placental Previa

1.38 (1.18-1.60)*

1.05 (0.91-1.21)

Pre-existing Diabetes

1.18 (0.97-1.44)

0.89 (0.73-1.08)

* p< 0.05
CI=confidence interval
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Appendix I. Unadjusted and adjusted risk ratios for fetal outcomes
Unadjusted Estimates
RR (95% CI)

Adjusted Estimates
RR (95% CI)

Treatment: No drug

Reference

Reference

Antipsychotic Only

1.13 (0.82-1.57)

1.11 (0.80-1.54)

Antidepressant Only

1.35 (0.86-2.12)

1.33 (0.85-2.09)

Antipsychotic and Antidepressant Polytherapy

1.24 (0.61-2.53)

1.16 (0.57-2.37)

Age Groups: 13-19

0.80 (0.50-1.27)

0.68 (0.41-1.13)

20-29

Reference

Reference

30-39

0.99 (0.79-1.24)

1.03 (0.80-1.31)

40-50

1.00 (0.54-1.82)

0.99 (0.50-1.94)

Number of Previous Births: 0

Reference

Reference

1

0.90 (0.70-1.14)

0.86 (0.66-1.11)

2+

0.70 (0.53-0.92)*

0.59 (0.43-0.80)*

Income: 1 - Lowest neighbourhood income quintile

Reference

Reference

2

1.02 (0.78-1.33)

1.05 (0.80-1.39)

3

0.86 (0.62-1.21)

0.80 (0.56-1.15)

4

1.05 (0.74-1.48)

1.04 (0.72-1.50)

5

1.17 (0.80-1.71)

1.05 (0.69-1.59)

Obesity

0.95 (0.70-1.29)

0.85 (0.61-1.19)

Alcohol Related Disorders

1.17 (0.92-1.48)

1.15 (0.88-1.51)

Substance Related Disorders

1.08 (0.88-1.33)

1.04 (0.81-1.32)

Pre-existing Diabetes

1.59 (0.95-2.66)

1.65 (0.94-2.91)

* p< 0.05
CI=confidence interval
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Appendix J. Unadjusted and adjusted risk ratios for labour and delivery outcomes
Unadjusted Estimates
RR (95% CI)

Adjusted Estimates
RR (95% CI)

Treatment: No drug

Reference

Reference

Antipsychotic Only

1.03 (0.94-1.12)

1.02 (0.93-1.11)

Antidepressant Only

1.04 (0.92-1.19)

1.03 (0.91-1.17)

Antipsychotic and Antidepressant Polytherapy

1.11 (0.93-1.33)

1.08 (0.91-1.30)

Age Groups: 13-19

0.91 (0.80-1.03)

0.83 (0.73-0.95)*

20-29

Reference

Reference

30-39

1.12 (1.06-1.19)*

1.15 (1.09-1.23)*

40-50

1.32 (1.18-1.47)*

1.36 (1.21-1.53)*

Number of Previous Births: 0

Reference

Reference

1

0.87 (0.82-0.93)*

0.83 (0.77-0.89)*

2+

0.81 (0.76-0.87)*

0.76 (0.70-0.82)*

Income: 1 - Lowest neighbourhood income quintile

Reference

Reference

2

1.00 (0.93-1.07)

1.00 (0.93-1.07)

3

1.03 (0.95-1.12)

1.03 (0.94-1.12)

4

1.02 (0.93-1.12)

1.00 (0.91-1.10)

5

1.02 (0.92-1.14)

1.01 (0.91-1.13)

Obesity

1.16 (1.08-1.24)*

1.12 (1.04-1.21)*

Pre-existing Diabetes

1.25 (1.11-1.41)*

1.18 (1.03-1.34)*

Epidural Use

1.11 (0.90-1.36)

1.13 (0.91-1.40)

* p< 0.05
CI=confidence interval
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Appendix K. Unadjusted and adjusted risk ratios psychiatric readmission outcomes
Unadjusted Estimates
RR (95% CI)

Adjusted Estimates
RR (95% CI)

Treatment: No drug

Reference

Reference

Antipsychotic Only

0.75 (0.39-1.43)

0.79 (0.40-1.58)

Antidepressant Only

1.13 (0.50-2.55)

1.22 (0.53-2.85)

Antipsychotic and Antidepressant Polytherapy

1.79 (0.68-4.72)

1.24 (0.39-4.00)

Age Groups: 13-19

0.49 (0.18-1.33)

0.42 (0.10-1.68)

20-29

Reference

Reference

30-39

1.34 (0.94-1.90)

1.51 (0.99-2.31)

40-50

0.55 (0.14-2.21)

0.42 (0.06-2.95)

Income: 1 - Lowest neighbourhood income quintile

Reference

Reference

2

0.80 (0.50-1.26)

0.71 (0.41-1.22)

3

0.82 (0.48-1.42)

1.01 (0.55-1.85)

4

1.08 (0.63-1.85)

0.64 (0.30-1.38)

5

0.96 (0.50-1.86)

0.83 (0.36-1.90)

History of Suicide Attempt

1.50 (0.92-2.44)

0.90 (0.45-1.79)

Prior Alcohol Related Disorders

1.41 (0.97-2.05)

0.88 (0.53-1.47)

Recurrence of Mood Episode in Current Pregnancy

3.41 (2.43-4.80)*

3.64 (2.36-5.63)*

Number of BD Hospitalizations Prior to Pregnancy

1.13 (1.09-1.16)*

1.09 (1.05-1.12)*

Psychiatric Emergency Department Visits Prior to
Pregnancy

1.09 (1.07-1.12)*

1.06 (1.02-1.10)*

* p< 0.05
CI=confidence interval
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